Antibody-drug conjugate, and pharmaceutical composition thereof, preparation therefor and use thereof
By linking TLR7/8 agonists with monoclonal antibodies to form antibody-drug conjugates, the problems of narrow therapeutic index and inconvenience of intratumoral injection of TLR7/8 agonist systems have been solved, achieving targeted delivery and immune agonistic activity, improving therapeutic efficacy and reducing systemic toxicity.
Patent Information
- Application Number
- PCT/CN2024/095313
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-06-07
- Filing Date
- 2024-05-24
- Publication Date
- 2024-12-12
AI Technical Summary
TLR7/8 agonists have a narrow therapeutic index when administered systemically, which limits their clinical development. Furthermore, intratumoral injection is inconvenient and leads to poor patient compliance.
To develop an antibody-drug conjugate that links a TLR7/8 agonist to a monoclonal antibody via a linker, thereby forming an antibody-drug conjugate that achieves targeted delivery, activates immune agonist activity, reduces systemic toxicity, and improves the therapeutic index.
The targeted delivery of TLR7/8 agonists was achieved through antibody-drug conjugates, which improved the therapeutic index, reduced systemic toxicity, and enhanced immune agonistic activity against tumors.
Smart Images

Figure PCTCN2024095313-FTAPPB-I100001 
Figure PCTCN2024095313-FTAPPB-I100002 
Figure PCTCN2024095313-FTAPPB-I100003
Abstract
Description
Antibody drug conjugate, and pharmaceutical composition, preparation and use thereof Technical Field
[0001] The present invention relates to the field of biomedicine. Specifically, the present invention provides an antibody-drug conjugate, and a pharmaceutical composition, preparation and use thereof. Background Art
[0002] TLR7 and TLR8 are important pathogen pattern recognition receptors. Upon ligand binding, they activate downstream signaling pathways, promoting the production of inflammatory cytokines. They play a crucial role in regulating both host innate and adaptive immunity and serve as effective targets for antiviral and tumor therapy. TLR7 is primarily expressed in B cells, monocytes, and plasmacytoid dendritic cells (pDCs), while TLR8 is primarily expressed in monocytes, neutrophils, and myeloid dendritic cells. Both TLR7 and 8 activate downstream inflammatory signaling molecules through a Myd-88-dependent signaling pathway. TLR7 activation favors the production of type I interferons (IFNs), such as IFN-α, while TLR8 favors activation of nuclear factor-κB (NF-κB), leading to the production of various inflammatory cytokines, such as TNF-α and IL-6. These cytokines can recruit or activate T cells, B cells, and natural killer (NK) cells within the disease microenvironment, enhancing both innate and adaptive immune responses. TLR7 / 8 agonists can activate antigen-presenting cells (APCs), exerting direct tumor cell-killing activity by enhancing their phagocytic function, or promoting T cell-mediated immune responses by enhancing the presentation of tumor neoantigens. Preclinical studies have shown that TLR7 / 8 agonists alone exhibit potent and broad-spectrum anti-tumor activity. TLR7 / 8 agonists activate a variety of immune cells and can promote the transformation of cold tumors into hot tumors, thereby promoting responses to immunotherapy. However, both preclinical and clinical studies suggest that the therapeutic index of TLR7 / 8 agonists is narrow when administered systemically, limiting their further clinical development. Therefore, an important research and development strategy now is targeted delivery or local administration, such as intratumoral injection. However, intratumoral injection is inconvenient to operate and patient compliance is very poor.
[0003] Antibody-drug conjugates (ADCs) are small molecule drugs with biological activity that are linked to monoclonal antibodies through a linker. Monoclonal antibodies act as carriers to target and transport small molecule drugs into target cells. Small molecules with biological activity are usually cytotoxic drugs. Such antibody-drug conjugates combine the powerful killing effect of traditional small molecule chemotherapy with the tumor targeting of antibody drugs. The targeted delivery of cytotoxic drugs is achieved by leveraging the targeting of antibody drugs, thereby improving the therapeutic index of cytotoxic drugs. By linking TLR7 / 8 agonists to monoclonal antibodies through linkers, a new type of antibody-drug conjugate is produced, which exerts immune stimulatory activity in target tissues, reduces systemic toxicity caused by systemic exposure, and can improve the therapeutic index of TLR7 / 8 agonists.
[0004] Summary of the Invention
[0005] The purpose of the present invention is to provide a new type of antibody-drug conjugate.
[0006] In a first aspect of the present invention, an immunoconjugate is provided, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or pharmaceutically acceptable salt or hydrate thereof, wherein the immunoconjugate comprises a structure as shown in Formula I: comprising an antibody covalently linked to a divalent linker, wherein the divalent linker is covalently linked to one or more toxin D moieties, and wherein the immunoconjugate has Formula I: Pc-[-LYD] N a (I)
[0007] in:
[0008] Pc is an antibody or antigen-binding fragment covalently linked to a divalent linker -LY-;
[0009] N a is the average number of connections, which is a decimal or integer greater than 0; preferably an integer or decimal from 1 to 20;
[0010] D is a toxin having a structure selected from the group consisting of Formula Ia, Formula Ib, Formula Ic, and Formula Id, wherein the toxin is covalently linked to a divalent linker -LY- via an N or S atom within the molecule:
[0011] in:
[0012] L 11 Selected from the group consisting of -O-, -NH-, -S-, -S(=O)-, or -S(=O)2-;
[0013] R1 is selected from the following group: H, C 1-12 Alkyl, C 2-12 Alkenyl, C2-12 Alkynyl, C 3-12 Cycloalkyl or 4-12 membered heterocycloalkyl; wherein said R1 may be further replaced by one or more R 1a Substituted by a substituent, and the R 1a Selected from the group consisting of hydrogen, halogen, hydroxy, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, -NR a1 R a2 、-NHC(=O)-R a3 , one or more R a4 Substituted 5-6 membered heteroaryl, -OC(=O)R a5 、-C(=O)R a5 、-OC(=O)OR a5 、-C(=O)OR a5 ;
[0014] The R a1 、R a2 、R a3 or R a4 Select from the following group: C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Cycloalkyl;
[0015] The R a5 Select from the following group: C 1-24 Alkyl, halogenated C 1-24 Alkyl, C 1-24 Heteroalkyl, wherein the heteroatom is selected from one or more of NH, N, O and S;
[0016] Said R2 and R3 are independently selected from the following groups: hydrogen, halogen, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, 5-8 membered heterocyclic aryl, or 5-8 membered aryl; wherein said R2 may be further substituted by one or more substituents selected from the group consisting of halogen, hydroxyl, cyano, or amino;
[0017] m is 0, 1, 2, 3, 4, 5, 6, 7 or 8;
[0018] B does not exist, or B is selected from the following group: C 3-12 Cycloalkyl, 4-12 membered heterocycloalkyl, C 6-12 Aryl, 5-12 membered heteroaryl or wherein each A is independently selected from C, CH or N, and R6 and R7 together with their adjacent carbon atoms form C4-7 Cycloalkylene or C 4-7 Heterocycloalkylene, the C 4-7 One or more methylene groups in a cycloalkylene group or a 4-7 membered heterocycloalkylene group may be independently replaced by a carbonyl group or S(=O)2; in the 4-7 membered heterocycloalkylene group, the heteroatom is selected from N, O, and S, and the number of heteroatoms is 1 to 3;
[0019] L 12 Selected from the group consisting of: None, -(CR 1b R 1c ) p -(NR 1d ) q -、-O-、-S-、-(CR 1b R 1c ) p -C(=O)-、-(CR 1b R 1c ) p -C(=O)NH-、-(CR 1b R 1c ) p -NHC(=O)-, -S(=O)- or -S(=O)2-; wherein R 1b 、R 1c Selected from the group consisting of hydrogen, halogen, C 1-6 Alkyl, C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl or C 1-6 Haloalkyl, R 1d Selected from the group consisting of hydrogen, C 1-6 Alkyl, C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, C 1-6 C substituted with haloalkyl or hydroxy 1-6 Alkyl, p is 0, 1, 2, 3, 4, 5 or 6, q is 0 or 1;
[0020] R4 is selected from the group consisting of hydrogen, halogen, cyano, amino, hydroxyl, C 1-12 Alkyl, C 1-12 Alkoxy, C 2-12 Alkenyl, C 2-12 Alkynyl, C 3- 12 Cycloalkyl, 4-12 membered heterocycloalkyl, C 6-12 Aryl or 5-12 membered heteroaryl; and said R4 may be optionally replaced by one or more R e Substituent substituted, where R e Selected from the group consisting of hydrogen, halogen, hydroxy, carboxylic acid, amino, C 1-6 Alkyl, one or more R e1 Substituted C 1-6 Alkyl, C 1-6Alkoxy, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 4-12 heterocycloalkyl, C 6-12 Aryl, 5-12 membered heteroaryl, -N(R e2 R e3 ), -C(=O)OR e2 、-C(=O)NH-R e2 、-S(=O)2-R e2 ;
[0021] And when L 12 is none and R 4 When H, B is selected from the following group: C 3-12 Cycloalkyl, 4-12 membered heterocycloalkyl, C 6-12 Aryl, 5-12 membered heteroaryl or wherein each A is independently selected from C, CH or N, and R6 and R7 together with their adjacent carbon atoms form C 4-7 Cycloalkylene or C 4-7 heterocycloalkylene;
[0022] R e1 Selected from the group consisting of halogen, hydroxyl;
[0023] R e2 、R e3 Selected from the group consisting of hydrogen, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 C substituted with haloalkyl or hydroxy 1-6 alkyl;
[0024] R5 is selected from the group consisting of halogen, hydroxy, cyano, amino, C 1-6 Alkyl, C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -C(=O)OR f 、-C(=O)NH-R f 、-S(=O)2-R f ; where R f Selected from the group consisting of hydrogen, C 1-6 Alkyl, C 3-6 Cycloalkyl or C 1-6 alkyl halide;
[0025] n is 1, 2, 3, 4, 5 or 6;
[0026] Wherein, each of the heterocyclic groups may be saturated or partially unsaturated (but not having an aromatic structure), and in the heterocyclic group, the heteroatom is selected from N, O, S, and the number of heteroatoms is 1, 2, 3 or 4 (preferably 1 or 2); in the heteroaryl group, the heteroatom is selected from N, O, S, and the number of heteroatoms is 1, 2 or 3.
[0027] In another preferred embodiment, the divalent linker LY has a structure as shown in the following formula: -L1-L2-L3-L4-Y-;
[0028] Wherein, the L1 is -SS-, R d is H, C1-C6 alkyl, C1-C6 deuterated alkyl, C3-C8 cycloalkyl or C3-C8 deuterated cycloalkyl;
[0029] The L2 is a group selected from the following group: -(CHR) m1 -, optionally substituted -(CHR) m1 -C(O)NH-(CH2CH2O) n3 -(CHR) m2 -, optionally substituted -(CH2CH2O) n3 -(CHR) m2 -, optionally substituted -(CHR) m1 -C(O)NH-(CH2CH2O) n3 -(CHR) m2 -C(O)-, optionally substituted -(CHR) m1 -(CH2CH2O) n3 -(CHR) m2 -、-(CHR) m1 -C(O)-, optionally substituted -(CHR) m1 -C(O)-L4-NH(CH2CH2O) n3 -(CHR) m2 -, optionally substituted -(CHR) m1 -C(O)NH-(CHR) m1 -5-10 membered aromatic heterocycle-(CH2CH2O) n3 -(CHR) m2 -, optionally substituted -(CHR) m1 -C(O)-L4-NH-(CH2CH2O) n3 -L4-(CHR) m2 -, optionally substituted -(CHR) m1 -C(O)-L4-NH(RCH) m1 -(OCH2CH2) n3 -L4-(CHR)m2 -, optionally substituted -(CHR) m1 -C3-C9 cycloalkyl-(CHR) m2 -, optionally substituted -(CHR) m1 -C3-C9 heterocycloalkyl-(CHR) m2 -;
[0030] The L4 is an optionally substituted group selected from the group consisting of: a chemical bond, Among them, the R a and R b Each is independently selected from the following group: hydrogen, optionally substituted C1-C4 alkyl, optionally substituted C1-C4 deuterated alkyl, CH2COOH;
[0031] The R 101 Selected from the group consisting of hydrogen, halogen, cyano, amino, hydroxyl, carboxyl, ester, C 1-12 Alkyl, C 1-12 Alkoxy, C 2-12 Alkenyl, C 2-12 Alkynyl, C 3-12 Cycloalkyl, 4-12 membered heterocycloalkyl, C 6-12 Aryl or 5-12 membered heteroaryl, -L4-C(O)-(CH2CH2O) n3 -R, -C(O)-NR-(CHR) m2 -NR-C(O)-(CH2CH2O) n3 -R;
[0032] L3 is the peptide residue [Am] p1 -: where p1 is 0, 1, 2, 3, 4, 5, 6, 7, or 8;
[0033] Y is selected from the group consisting of -C(O)-, -OC(O)-, -NHC(O)-, -NR-(CHR) m2 -NR-C(O)-、-NR-(CHR) m2 -NR- C(O)O-(CHR) m1 -, chemical bond;
[0034] Wherein, each of the R's is independently selected from the following groups: H, D, (CH2) n4 NHC(O)NH2, C1-C6 alkyl;
[0035] m1, m2 and n3 are each independently selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12;
[0036] m101 is selected from 0, 1, 2, 3, 4;
[0037] Unless otherwise specified, the term "substituted" refers to the substitution of one or more hydrogen atoms on a group by a substituent selected from the group consisting of a hydrogen atom, a deuterium atom, a halogen, a nitrile group, a nitro group, a hydroxyl group, an amino group, a C1-C6 alkyl-NH-, a (C1-C6 alkyl)2N-, a C1-C6 alkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy group, a halogenated C1-C6 alkyl group, a halogenated C2-C6 alkenyl group, a halogenated C2-C6 alkynyl group, a halogenated C1-C6 alkoxy group, an allyl group, a benzyl group, a C6-C6 alkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a halogenated C1-C6 alkoxy group, an allyl group, a benzyl group, a C6-C6 alkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy group, a C1-C6 alkyl group, a C2 ... 12 Aryl, C1-C6 alkoxy-C1-C6 alkyl, C1-C6 alkoxy-carbonyl, phenoxycarbonyl, C2-C6 alkynyl-carbonyl, C2-C6 alkenyl-carbonyl, C3-C6 cycloalkyl-carbonyl, C1-C6 alkyl-sulfonyl, phenyl, 5-7 membered heteroaryl, C3-C8 cycloalkyl, 3-12 membered heterocyclyl, or C(O)NH-L2H.
[0038] In another preferred embodiment, the L1 is
[0039] In another preferred embodiment, the L2 is a group selected from the group consisting of: optionally substituted -(CHR) m1 -, optionally substituted -(CHR) m1 -C(O)NH-(CH2CH2O) n3 -(CHR) m2 -, optionally substituted -(CHR) m1 -(CH2CH2O) n3 -(CHR) m2 -;
[0040] p1 is 0;
[0041] The L4 is a chemical bond.
[0042] In another preferred embodiment, the L2 is a group selected from the group consisting of: optionally substituted -(CHR) m1 -C(O)NH-(CH2CH2O) n3 -(CHR) m2 -;
[0043] p1 is 0;
[0044] The L4 is a chemical bond.
[0045] In another preferred embodiment, the L2 is a group selected from the group consisting of: optionally substituted -(CHR) m1 -, optionally substituted -(CHR) m1 -(CH2CH2O) n3 -(CHR)m2 -;
[0046] p1 is 0;
[0047] The L4 is a chemical bond.
[0048] In another preferred embodiment, the L2 is a group selected from the group consisting of: optionally substituted -(CHR) m1 -C(O)-;
[0049] p1 is 1, 2, or 3;
[0050] The L4 is an optionally substituted group selected from the following group:
[0051] In another preferred embodiment, the L2 is a group selected from the group consisting of: optionally substituted (CHR) m1 -C(O)-;
[0052] p1 is 1, 2, or 3;
[0053] The L4 is an optionally substituted group selected from the following group:
[0054] In another preferred embodiment, the L2 is a group selected from the group consisting of: optionally substituted -(CH2) m1 -C(O)-, optionally substituted -(CH2CH2O) n3 -(CHR) m2 -C(O)-, optionally substituted -(CHR) m1 -C3-C9 cycloalkyl-(CHR) m2 -; Preferably, m1 and m2 are each independently selected from 0, 1, 2, 3, 4 or 5; n3 is selected from 0, 1 or 2;
[0055] p1 is 0;
[0056] The L4 is a chemical bond, or an optionally substituted group selected from the following group:
[0057] In another preferred embodiment, the L2 is a group selected from the group consisting of: optionally substituted -(CHR) m1 -C(O)-L4-NH(RCH) m1 -(OCH2CH2) n3 -(CHR) m2 -, optionally substituted -(CHR) m1 -C(O)NH-(CHR) m1 -5-10 membered aromatic heterocycle-(CH2CH2O)n3 -(CHR) m2 -, optionally substituted -(CHR) m1 -C(O)-L4-NH-(CH2CH2O) n3 -L4-(CHR) m2 -, optionally substituted -(CHR) m1 -C(O)-L4-NH(RCH) m1 -(OCH2CH2) n3 -L4-(CHR) m2 -; Preferably, the 5- to 10-membered aromatic heterocycle is a 5- or 6-membered aromatic heterocycle
[0058] p1 is 0;
[0059] The L4 is a chemical bond, or an optionally substituted group selected from the following group:
[0060] In another preferred embodiment, L3 is a peptide residue composed of amino acids selected from the following group: phenylalanine, isoleucine, leucine, tryptophan, valine, methionine, tyrosine, alanine, threonine, histidine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, proline, citrulline, aspartic acid and glycine.
[0061] In another preferred embodiment, the L3 is a peptide residue consisting of amino acids selected from the following group: glycine, alanine, lysine, phenylalanine, valine and citrulline.
[0062] In another preferred embodiment, L3 is a peptide residue selected from the following group: -Glycine-Phenylalanine-Glycine-(-Gly-Phe-Gly-), -Glycine-Glycine-Phenylalanine-Glycine-(-Gly-Gly-Phe-Gly-), -Valine-Citrulline-(-Val-Cit-), -Citrulline-Valine-(-Cit-Val-), -Citrulline-Alanine-(-Cit-Ala-), -Valine-Alanine-(-Val-Ala-), -Valine-Arginine-(-Val-Arg-), -Valine-Lysine-(-Val-Lys-), -Valine-Lysine (Ac)-(-V al-Lys(Ac)-), -Lysine-Valine-(-Lys-Val-), -Leucine-Citrulline-(-Leu-Cit-), -Isoleucine-Citrulline-(-Ile-Cit-), -Tryptophan-Citrulline-(-Trp-Cit-), -Phenylalanine-Lysine-(-Phe-Lys-), -Phenylalanine-Lysine(Ac)-(-Phe-Lys(Ac)-), -Phenylalanine-Citrulline-(-Phe-Cit-), -Phenylalanine-Ala-(-Phe-Ala-), -Phenylalanine-Arginine-(-Phe-Arg-), -Alanine-Lysine-(-Ala-Lys -), -Alanine-Alanine-(-Ala-Ala-), -Alanine-Alanine-Alanine-(-Ala-Ala-Ala-), -Alanine-Alanine-Asparagine-(-Ala-Ala-Asn-), -Alanine-Alanine-Aspartic Acid-(Ala-Ala-Asp-), -Lysine-Alanine-Alanine-Asparagine-(-Lys-Ala-Ala-Asn-), -Lysine-Alanine-Alanine-Aspartic Acid-(-Lys-Ala-Ala-Asp-), -(D)-Valine-Leucine-Lysine-(-D-Val-Leu-Lys-), -Glycine-Glycine-Arginine -Glycine-Glycine-Asparagine-(-Gly-Gly-Asn-), -Glycine-Glycine-Phenylalanine-(-Gly-Gly-Phe-), -Valine-Lysine-Glycine-(-Val-Lys-Gly-), -Glutamic Acid-Alanine-Alanine-(-Glu-Ala-Ala-), -Aspartic Acid-Alanine-Alanine-(-Asp-Ala-Ala-), -Valine-Lysine-Glycine-Glycine-(-Val-Lys-Gly-Gly-), and -Lysine-Alanine-Asparagine-(-Lys-Ala-Asn-).
[0063] In another preferred embodiment, the L3 is a structure selected from the following group:
[0064] In another preferred embodiment, L4 is a chemical bond, or an optionally substituted group selected from the following group:
[0065] Among them, the R a and R b Each is independently selected from the following group: hydrogen, optionally substituted C1-C4 alkyl, optionally substituted C1-C4 deuterated alkyl.
[0066] In another preferred embodiment, L4 is a chemical bond, or an optionally substituted structure selected from the following group:
[0067] In another preferred embodiment, Y is -C(O)-, -OC(O)-, -NHC(O)-, or a chemical bond.
[0068] In another preferred embodiment, L 11 Selected from the group consisting of -O-, -NH- or -S-.
[0069] In another preferred embodiment, L 11 It is -NH-.
[0070] In another preferred embodiment, m is 1 or 2.
[0071] In another preferred embodiment, R1 is selected from the following group: C 1-12 Alkyl, C 2-12 Alkenyl, C 2-12 Alkynyl, C 3-12 Cycloalkyl or 4-12 membered heterocycloalkyl; and said R1 may be further replaced by one or more R 1a Substituted by a substituent, and the R 1a Selected from the group consisting of halogen, hydroxy, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, -NR a1 R a2 、-NHC(=O)-R a3 , one or more R a4 Substituted 5-6 membered heteroaryl, -OC(=O)R a5 、-C(=O)R a5 、-OC(=O)OR a5 、-C(=O)OR a5 .
[0072] In another preferred embodiment, the R1 is selected from the following group: C 1-12 Alkyl, C 2-12Alkenyl, C 2-12 Alkynyl, C 3-12 Cycloalkyl or 4-12 membered heterocycloalkyl; and said R1 may be further replaced by one or more R 1a Substituted by a substituent, and the R 1a Selected from the group consisting of halogen, hydroxy, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl.
[0073] In another preferred embodiment, R1 is selected from the following group: H, C 1-8 Alkyl, C 1-8 Alkoxy, C 2-8 Alkenyl, C 2-8 Alkynyl, C 3-8 Cycloalkyl or 4-8 membered heterocycloalkyl; wherein said R1 may be further replaced by one or more R 1a Substituted by a substituent, and the R 1a Selected from the group consisting of hydrogen, halogen, hydroxy, cyano, C 1-4 Alkyl, C 1-4 Alkoxy.
[0074] In another preferred embodiment, the R1 is selected from the following group: C 1-8 Alkyl; and said R1 may be further replaced by one or more R 1a Substituted by a substituent, and the R 1a Select from the following group: C 1-6 Alkyl, C 3-6 Cycloalkyl.
[0075] In another preferred embodiment, B does not exist, or B is selected from the following group: C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 aryl, or
[0076] In another preferred embodiment, the B is absent, or B is selected from the following group: phenyl, pyridyl.
[0077] In another preferred embodiment, L 12 Selected from the group consisting of: -(CR 1b R 1c ) p -(NR 1d ) q -、-O-、-S-、-(CR 1b R 1c ) p -C(=O)-、-(CR 1b R 1c ) p -C(=O)NH-、-(CR 1bR 1c ) p -NHC(=O)-, -S(=O)- or -S(=O)2-; wherein R 1b 、R 1c Selected from the group consisting of hydrogen, halogen, C 1-6 Alkyl; R 1d is hydrogen or C 1-6 Alkyl; p is 0, 1, 2 or 3, and q is 0 or 1.
[0078] In another preferred embodiment, the L 12 Selected from the group consisting of: -(CH2) p -、-(CH2) p -NR 1d -、-O-、-S-、-(CH2) p -C(=O)-, -(CH2) p -C(=O)NH-, -(CH2) p -NHC(=O)-; wherein R 1d is hydrogen or C 1-6 Alkyl; p is 0, 1, 2 or 3.
[0079] In another preferred embodiment, R4 is selected from the group consisting of hydrogen, halogen, amino, hydroxyl, C 1-12 Alkyl, C 1-12 Alkoxy, C 2-12 Alkenyl, C 2- 12 Alkynyl, C 3-10 Cycloalkyl, 4-10 membered heterocyclic group, C 6-12 Aryl, or 5-12 membered heteroaryl; and said R4 may be optionally replaced by one or more R e Substituent substituted; wherein R e Selected from the group consisting of hydrogen, halogen, hydroxy, carboxylic acid, amino, C 1-6 Alkyl, one or more R e1 Substituted C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, phenyl, 5-7 membered heteroaryl, -N(R e2 R e3 ); where R e1 Selected from the group consisting of halogen, hydroxy, -P(O)(OR e2 )2; R e2 、R e3 Selected from the group consisting of hydrogen, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 C substituted with haloalkyl or hydroxy 1-6alkyl.
[0080] In another preferred embodiment, R5 is selected from the following groups: halogen, hydroxyl, cyano, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl.
[0081] In another preferred embodiment, the R4 is selected from the following group: hydrogen, C 1-12 Alkyl, C 1-12 Alkoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or a group formed by losing a hydrogen atom from a ring selected from the following group:
[0082] And the R4 can be optionally replaced by one or more R e Substituent substitution.
[0083] In another preferred embodiment, R5 is selected from the following groups: halogen, hydroxyl, cyano, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl.
[0084] In another preferred embodiment, R5 is selected from the following groups: halogen, C 1-4 Alkyl, C 1-4 Alkoxy.
[0085] In another preferred embodiment, the toxin is selected from the following group:
[0086] In another preferred embodiment, the antibody is selected from the following group: murine antibody, chimeric antibody, humanized antibody and fully human antibody.
[0087] In another preferred embodiment, the antibody is a monoclonal antibody.
[0088] In another preferred embodiment, the antibody is an antibody selected from the following group: anti-HER2 (ErbB2) antibody, anti-CD20 antibody, anti-TLR7 antibody, anti-EGFR antibody, anti-B7-H3 antibody, anti-c-Met antibody, anti-HER3 (ErbB3) antibody, anti-HER4 (ErbB4) antibody, anti-CD22 antibody, anti-CD30 antibody, anti-CD33 antibody, anti-CD44 antibody, anti-CD56 antibody, anti-CD70 antibody, anti-CD73 antibody, anti-CD105 antibody, anti-CEA antibody, anti-A33 antibody, anti-Cripto antibody, anti-EphA2 antibody, anti-G250 antibody, anti-MUCl antibody, anti-Lewis Y antibody, anti-VEGFR antibody, anti-GPNMB antibody, anti-Integrin antibody, anti-PSMA antibody, anti-Trop-2 antibody, anti-DLL3 antibody, anti-Tenascin-C antibody, anti-SLC44A4 antibody and anti-Mesothelin antibody;
[0089] Preferably, the antibody is selected from Trastuzumab (Herceptin), Rituximab, Pertuzumab, Nimotuzumab, Enoblituzumab, Emibetuzumab, Inotuzumab, Pinatuzumab, Brentuximab, Gemtuzumab, Bivatuzumab, Lorvotuzumab, cBR96 and Glematumamab.
[0090] In another preferred embodiment, the immunoconjugate is selected from the following group:
[0091] In a second aspect of the present invention, there is provided an immunoconjugate precursor, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or a pharmaceutically acceptable salt or hydrate thereof, wherein the immunoconjugate precursor comprises the structure shown in Formula IA: LD(IA),
[0092] Where L is L 1A -L2-L3-L4-Y-; among them, L 1A for Among them, R d is H, C1-C6 alkyl, C1-C6 deuterated alkyl, C3-C8 cycloalkyl or C3-C8 deuterated cycloalkyl;
[0093] D is defined as described in the first aspect of the present invention.
[0094] In another preferred embodiment, the immunoconjugate precursor is selected from the following group:
[0095] In a third aspect of the present invention, there is provided a linker precursor as shown in formula (L-1), which is used to obtain a ligand-drug conjugate formed by connecting a drug unit to a ligand: 1A -L2-L3-L4-YR g (L-1),
[0096] Among them, L 1A for Among them, R d is H, C1-C6 alkyl, C1-C6 deuterated alkyl, C3-C8 cycloalkyl or C3-C8 deuterated cycloalkyl; R g are H, OH, O(C1-C6 alkyl), O(p-nitrophenyl); the definitions of the remaining groups are as described in the first aspect of the present invention.
[0097] The fourth aspect of the present invention provides a pharmaceutical composition comprising the immunoconjugate according to the first aspect of the present invention, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or its pharmaceutically acceptable salt, prodrug or solvate, and optionally a pharmaceutically acceptable carrier, diluent or excipient.
[0098] The fifth aspect of the present invention provides an immunoconjugate as described in the first aspect of the present invention, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or its pharmaceutically acceptable salt, prodrug or solvate, and / or the pharmaceutical composition as described in the fourth aspect of the present invention in the preparation of a medicament for treating or preventing viral infection or tumor.
[0099] In another preferred embodiment, the tumor is a cancer associated with abnormally increased activity or expression of TLR7, HER2, HER3, B7H3, CD20 or EGFR.
[0100] In another preferred embodiment, the tumor is a tumor related to the expression of the target targeted by the antibody in the immunoconjugate; preferably, the tumor includes a tumor with high expression of the target and / or a tumor positive for the target.
[0101] In another preferred embodiment, the cancer is preferably selected from melanoma, non-small cell lung cancer, hepatocellular carcinoma, basal cell carcinoma, renal cell carcinoma, myeloma, allergic rhinitis, asthma, COPD, ulcerative colitis, liver fibrosis, breast cancer, ovarian cancer, cervical cancer, uterine cancer, prostate cancer, kidney cancer, urethra cancer, bladder cancer, liver cancer, gastric cancer, endometrial cancer, salivary gland cancer, esophageal cancer, glioma, neuroblastoma, sarcoma, lung cancer, colon cancer, rectal cancer, colorectal cancer, leukemia, disease, bone cancer, skin cancer, thyroid cancer, pancreatic cancer and lymphoma; or, use in the preparation of a medicament for treating an infection caused by a virus, wherein the virus is selected from the group consisting of dengue virus, yellow fever virus, West Nile virus, Japanese encephalitis virus, tick-borne encephalitis virus, Kunjin virus, Murray Valley encephalitis virus, St. Louis encephalitis virus, Omsk hemorrhagic fever virus, bovine viral diarrhea virus, Zika virus, HIV, HBV, HCV, HPV, RSV, SARS and influenza virus.
[0102] In a sixth aspect of the present invention, there is provided a linker as shown in formula (L-2), which connects the drug unit to the ligand to form a ligand-drug conjugate: -L1-L2-L3-L4-Y-(L-2),
[0103] Wherein, the definitions of L1, L2, L3, L4, and Y are as described in the first aspect of the present invention.
[0104] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features described in detail below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Due to space limitations, they will not be listed here one by one. DETAILED DESCRIPTION
[0105] Based on long-term and in-depth research, the inventors have developed a novel class of ADC drugs with good efficacy and enhanced safety. Based on the above findings, the inventors have completed the present invention.
[0106] the term
[0107] As used herein, the term "alkyl" includes straight or branched chain alkyl groups. For example, C1-C8 alkyl groups represent straight or branched chain alkyl groups having 1 to 8 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, and the like.
[0108] As used herein, the term "alkenyl" includes straight or branched alkenyl groups. For example, C2-C6 alkenyl refers to a straight or branched alkenyl group having 2 to 6 carbon atoms, such as vinyl, allyl, 1-propenyl, isopropenyl, 1-butenyl, 2-butenyl, or the like.
[0109] As used herein, the term "alkynyl" includes straight or branched chain alkynyl groups. For example, C2-C6 alkynyl refers to a straight or branched chain alkynyl group having 2 to 6 carbon atoms, such as ethynyl, propynyl, butynyl, or the like.
[0110] As used herein, the term "C3-C 10 "Cycloalkyl" refers to a cyclic alkyl group having 3 to 10 carbon atoms. It may be a monocyclic ring, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or the like. It may also be a bicyclic ring, such as a bridged ring or a spiro ring.
[0111] As used herein, the term "C1-C8 alkylamino" refers to an amino group substituted by a C1-C8 alkyl group, which may be monosubstituted or disubstituted; for example, methylamino, ethylamino, propylamino, isopropylamino, butylamino, isobutylamino, tert-butylamino, dimethylamino, diethylamino, dipropylamino, diisopropylamino, dibutylamino, diisobutylamino, di-tert-butylamino, etc.
[0112] As used herein, the term "C1-C8 alkoxy" refers to a straight or branched alkoxy group having 1 to 8 carbon atoms; for example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tert-butoxy, etc.
[0113] As used herein, the term "3-10 membered heterocycloalkyl group having 1-3 heteroatoms selected from the group consisting of N, S, and O" refers to a saturated or partially saturated cyclic group having 3-10 atoms, 1-3 of which are heteroatoms selected from the group consisting of N, S, and O. It may be a monocyclic or bicyclic ring, such as a bridged ring or a spirocyclic ring. Specific examples include oxetane, azetidine, tetrahydro-2H-pyranyl, piperidinyl, tetrahydrofuranyl, morpholinyl, and pyrrolidinyl.
[0114] As used herein, the term "C6-C 10 The term "aryl" refers to an aromatic group having 6 to 10 carbon atoms, for example, phenyl or naphthyl and the like.
[0115] As used herein, the term "5-10 membered heteroaryl having 1-3 heteroatoms selected from the group consisting of N, S, and O" refers to a cyclic aromatic group having 5-10 atoms, 1-3 of which are heteroatoms selected from the group consisting of N, S, and O. It may be a monocyclic or condensed ring. Specific examples include pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, pyrrolyl, pyrazolyl, imidazolyl, (1,2,3)-triazolyl and (1,2,4)-triazolyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, and oxazolyl.
[0116] Unless otherwise specified, the chain groups herein (such as alkyl, haloalkyl or deuterated alkyl) have 1-10 carbon atoms, preferably 1-6 carbon atoms, or 1-4 carbon atoms; the non-aromatic cyclic groups herein (such as cycloalkyl, heterocycloalkyl, alicyclic, alicyclic heterocyclic, etc.) are 3-12 members, preferably 3-8 members, 3-6 members; the aromatic cyclic groups herein (such as aryl, heteroaryl, etc.) are 5-15 members, such as 6-10 membered aryl, 5-7 membered heteroaryl, 5-10 membered heteroaryl, etc.
[0117] Unless otherwise specified as "substituted or unsubstituted", the groups of the present invention may be substituted by substituents selected from the following groups: halogen, nitrile, nitro, hydroxyl, amino, C1-C6 alkyl-amino, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, halogenated C1-C6 alkyl, halogenated C2-C6 alkenyl, halogenated C2-C6 alkynyl, halogenated C1-C6 alkoxy, allyl, benzyl, C6-C 12 Aryl, C1-C6 alkoxy-C1-C6 alkyl, C1-C6 alkoxy-carbonyl, phenoxycarbonyl, C2-C6 alkynyl-carbonyl, C2-C6 alkenyl-carbonyl, C3-C6 cycloalkyl-carbonyl, C1-C6 alkyl-sulfonyl, etc.
[0118] As used herein, "halogen" or "halogen atom" refers to F, Cl, Br, and I. More preferably, the halogen or halogen atom is selected from F, Cl, and Br. "Halogenated" means substituted with an atom selected from F, Cl, Br, and I.
[0119] Unless otherwise specified, the structural formulas described herein are intended to include all isomeric forms (e.g., enantiomers, diastereomers, and geometric isomers (or conformers)): for example, R and S configurations containing asymmetric centers, (Z) and (E) isomers of double bonds, etc. Therefore, single stereochemical isomers of the compounds of the present invention or mixtures of their enantiomers, diastereomers, or geometric isomers (or conformers) are all within the scope of the present invention.
[0120] As used herein, the term "tautomer" refers to structural isomers of different energies that can interconvert across a low energy barrier. For example, proton tautomers (i.e., prototropy) include interconversion via proton migration, such as 1H-indazole and 2H-indazole. Valence tautomers include interconversion via reorganization of some of the bonding electrons.
[0121] As used herein, the term "hydrate" refers to a complex formed by coordination of a compound of the present invention with water.
[0122] The compounds of the present application can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining specific embodiments with other chemical synthesis methods, and equivalent replacement methods well known to those skilled in the art. Preferred embodiments include but are not limited to the examples of the present application.
[0123] The solvents used in this application can be obtained commercially, and the compounds can be artificially or Software naming, commercially available compounds use supplier catalog names.
[0124] In this application, the term "ligand" generally refers to a macromolecular compound that can recognize and bind to an antigen or receptor associated with a target cell. The function of a ligand can be to present a drug to a target cell population bound to the ligand. These ligands include, but are not limited to, protein hormones, lectins, growth factors, antibodies, or other molecules that can bind to cells, receptors, and / or antigens. In this application, a ligand can be represented by Ab. The ligand antigen forms a linker bond with a linker through a heteroatom on the ligand. It can be an antibody or an antigen-binding fragment thereof. The antibody can be selected from a chimeric antibody, a humanized antibody, a fully human antibody, or a murine antibody; the antibody can be a monoclonal antibody.
[0125] As used herein, the term "peptide residue" generally refers to a residue comprising one or more amino acid residues linked together. For example, one or more amino acids in a polypeptide residue may be optionally substituted. For example, a polypeptide residue herein may comprise glycine-glycine-phenylalanine-glycine (Gly-Gly-Phe-Gly).
[0126] In this application, the term "Drug unit" generally refers to a chemical moiety that is directly or indirectly conjugated to an antibody or antigen-binding fragment to form an immunoconjugate. For example, a "Drug unit" includes, but is not limited to, a compound with anti-tumor activity as described herein. For example, a Drug unit includes a topoisomerase inhibitor.
[0127] As used herein, the term "compound with anti-tumor activity" generally refers to a compound that has the ability to reduce the proliferation rate, viability, or metastatic activity of tumor cells. For example, anti-tumor activity can be demonstrated by a decrease in the growth rate of abnormal cells or a stabilization or reduction in tumor size during treatment, or by a prolonged survival period resulting from treatment compared to a control without treatment. Anti-tumor activity can be assessed using recognized in vitro or in vivo tumor models, such as xenograft models.
[0128] In this application, the term "comprising" generally refers to including the features specified but not excluding other elements. The terms "above" and "below" generally refer to including the number.
[0129] In this application, the term "about" generally refers to a variation within a range of 0.5%-10% above or below the specified value, for example, a variation within a range of 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10% above or below the specified value.
[0130] In the present application, the compounds of the present application include tautomers, meso-racemates, racemates, enantiomers, and / or diastereomers of the compounds.
[0131] In the present application, some atoms of the compounds of the present application may appear in more than one isotopic form. For example, hydrogen may appear in the form of protium ( 1 H), deuterium ( 2 H) and tritium ( 3 H), carbon can exist in three different isotopes ( 12 C. 13 C and 14 C) naturally occurring. Examples of isotopes that can be incorporated into the compounds of the present application also include, but are not limited to 15 N. 18 O. 17 O. 18 F. 32 P. 33 P. 129 I. 131 I. 123 I. 124 I. 125 I, or similar isotopes. Therefore, relative to the natural abundance of these isotopes, the compounds of the present application may be in one or more of these isotopically enriched forms. As known to those skilled in the art, such isotopically enriched compounds can be used for a variety of purposes. For example, with heavy isotopes such as deuterium ( 2 H) substitution may offer certain therapeutic advantages, possibly due to greater metabolic stability.
[0132] As used herein, the term "pharmaceutical composition" generally refers to a mixture containing one or more compounds described herein, or their physiologically / pharmaceutically acceptable salts or prodrugs, and other chemical components, as well as other components such as physiologically / pharmaceutically acceptable carriers and excipients. Pharmaceutical compositions can facilitate administration to an organism, facilitating absorption of the active ingredient and thereby exerting its biological activity. Conventional pharmaceutical compositions can be prepared using techniques commonly used in the art.
[0133] In this application, the term "pharmaceutically acceptable salt" or "pharmaceutically usable salt" generally refers to a salt of the compound or ligand-drug conjugate of the present application, or a salt of the compound described in the present application. Such salts may be safe and / or effective when used in mammals and may have the desired biological activity. The antibody-antibody drug conjugate compound of the present application may form a salt with an acid. Non-limiting examples of pharmaceutically acceptable salts include: hydrochloride, hydrobromide, hydroiodide, sulfate, bisulfate, citrate, acetate, succinate, ascorbate, oxalate, nitrate, sorbate, hydrogen phosphate, dihydrogen phosphate, salicylate, hydrogen citrate, tartrate, maleate, fumarate, formate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, or p-toluenesulfonate.
[0134] In the present application, the term "conjugate" generally refers to a compound prepared by one or more chemical reactions of the compounds of the present application, or connected to each other through one or more connecting structures such as a bridge, a spacer, or a connecting part.
[0135] In this application, the term "pharmaceutically acceptable carrier" generally refers to a carrier for administering therapeutic agents, such as antibodies or polypeptides, genes and other therapeutic agents. The term refers to any pharmaceutical carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition and can be administered without excessive toxicity. For example, a pharmaceutically acceptable carrier can be distinguished from a nucleic acid vector used to contain a target gene in genetic engineering. Suitable carriers can be large, slowly metabolized macromolecules, such as proteins, polysaccharides, polylactic acid, polyglycolic acid, polyamino acids, amino acid copolymers, lipid aggregates and inactivated viral particles. These carriers are well known to those skilled in the art. Pharmaceutically acceptable carriers in therapeutic compositions may include liquids, such as water, saline, glycerol and ethanol. Auxiliary substances, such as wetting agents or emulsifiers, pH buffer substances, etc., may also be present in these carriers.
[0136] In this application, "antibody" can generally cover monoclonal antibodies, polyclonal antibodies, dimers, multimers, multispecific antibodies (such as bispecific antibodies) and antibody fragments, as long as they show the desired biological activity. Antibodies can be mouse, human, humanized, chimeric antibodies or derived from other species. Antibodies are proteins produced by the immune system that can recognize and bind to specific antigens. Target antigens generally have a large number of binding sites, also known as epitopes, that are recognized by the CDRs of multiple antibodies. Each antibody that specifically binds to different epitopes has a different structure. Therefore, an antigen can have more than one corresponding antibody. Antibodies include full-length immunoglobulin molecules or immunologically active portions of full-length immunoglobulin molecules, i.e., molecules containing antigens or portions thereof that specifically bind to targets of interest, such targets including, but not limited to, cancer cells or cells that produce autoimmune antibodies associated with autoimmune diseases. The immunoglobulins described herein can be of any type (e.g., IgG, IgE, IgM, IgD, and IgA), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2, or any mutation thereof), or subclass of immunoglobulin molecules. Immunoglobulins can be derived from any species. However, in one aspect, the immunoglobulins are derived from humans, mice, or rabbits. "Antibody fragments" can comprise a portion of a full-length antibody, generally its antigen-binding region or variable region. Examples of antibody fragments include: Fab, Fab', F(ab')2, and Fv fragments; diabodies; linear antibodies; minibodies; fragments prepared from Fab expression libraries; anti-idiotypic (anti-Id) antibodies; CDRs (complementarity determining regions); and any of the above epitope-binding fragments that immunospecifically bind to cancer cell antigens, viral antigens, or microbial antigens; single-chain antibody molecules; and multispecific antibodies formed from antibody fragments. The antibodies that constitute the antibody-drug conjugates herein can retain their original antigen-binding ability in the wild-type state. Therefore, the antibodies in the present application can, for example, specifically bind to antigens. The antigens involved include, for example, tumor-associated antigens (TAAs), cell surface receptor proteins and other cell surface molecules, cell survival regulators, cell proliferation regulators, molecules related to tissue growth and differentiation (such as known or predicted functional), lymphokines, cytokines, molecules involved in cell cycle regulation, molecules involved in angiogenesis, and molecules related to angiogenesis (such as known antibodies). The antigens bound by antibodies can be one or a subset of the above categories, while other subsets contain other molecules / antigens with special properties (compared to the target antigen). Antibodies used in antibody drug conjugates include, but are not limited to, antibodies against cell surface receptors and tumor-associated antigens. Such tumor-associated antigens are well known in the industry and can be prepared by antibody preparation methods and information well known in the industry.These targets can be specifically expressed on the surface of one or more cancer cells, while being little or not expressed on the surface of one or more non-cancerous cells. Generally, such tumor-associated polypeptides can be more overexpressed on the surface of cancer cells than on the surface of non-cancerous cells.
[0137] In this application, the term "chimeric antibody" generally refers to an antibody formed by fusing the variable region of a murine antibody with the constant region of a human antibody, which can reduce the immune response induced by the murine antibody. To create a chimeric antibody, a hybridoma that secretes a murine-specific monoclonal antibody can be established. The variable region genes can then be cloned from the murine hybridoma cells. The constant region genes of a human antibody can then be cloned as needed. The murine variable region genes and the human constant region genes can then be linked to form a chimeric gene, which is then inserted into an expression vector. The chimeric antibody molecule can then be expressed in either eukaryotic or prokaryotic systems.
[0138] In this application, the term "humanized antibody", also known as CDR-grafted antibody, generally refers to antibodies produced by transplanting mouse CDR sequences into human antibody variable region frameworks, i.e., different types of human germline antibody framework sequences. This can overcome the heterologous reactions induced by chimeric antibodies due to the large amount of mouse protein components they carry. Such framework sequences can be obtained from public DNA databases or published references that include germline antibody gene sequences. For example, the germline DNA sequences of human heavy and light chain variable region genes can be found in the "VBase" human germline sequence database.
[0139] In this application, the terms "fully human antibody", "fully human antibody" or "completely human antibody" are also called "fully human monoclonal antibody", and the variable region and constant region of the antibody can be both human, eliminating immunogenicity and toxic side effects. The development of monoclonal antibodies has gone through four stages, namely: murine monoclonal antibodies, chimeric monoclonal antibodies, humanized monoclonal antibodies and fully human monoclonal antibodies. The antibody or ligand described in this application can be a fully human monoclonal antibody. Related technologies for the preparation of fully human antibodies can be: human hybridoma technology, EBV-transformed B lymphocyte technology, phage display technology (phage display), transgenic mouse antibody preparation technology (transgenic mouse) and single B cell antibody preparation technology, etc.
[0140] In the present application, the term "linker" generally refers to a chemical structure fragment or bond that is connected to one group at one end and to another group at the other end, and can also be connected to other linkers before being connected to the drug and / or ligand. The directly or indirectly connected ligand can refer to the group being directly connected to the ligand through a covalent bond, or it can be connected to the ligand through a linker. For example, the linker can be the structure shown in the linker described in the present application. For example, a chemical structure fragment or bond containing an acid-labile linker structure (such as a hydrazone), a protease-sensitive (such as a peptidase-sensitive) linker structure, a photolabile linker structure, a dimethyl linker structure, or a disulfide-containing linker structure can be used as a linker.
[0141] In this application, the term "linking group" generally refers to a group capable of connecting to another group. For example, a compound having a linking group can be connected to another group through a coupling reaction between the linking group and the other group. For example, a maleimide group can serve as a linking group.
[0142] In this application, the term "disease associated with the expression of a target" generally means that the occurrence and / or progression of the disease is associated with the expression level of the target. For example, the expression level of a target in cells from a disease area, such as a specific tissue or organ of a patient, is increased relative to the expression level of normal cells from the tissue or organ, i.e., highly expressed. Or, for example, the expression level of a target in cells from a disease area, such as a specific tissue or organ of a patient, is decreased relative to the expression level of normal cells from the tissue or organ, i.e., low expressed. Or, for example, cells from a disease area, such as a specific tissue or organ of a patient, express a target, i.e., are positive. Or, for example, cells from a disease area, such as a specific tissue or organ of a patient, do not express a target, i.e., are negative. For example, the characteristics of target expression can be determined by standard assays known in the art.
[0143] As used herein, the term "effective amount" generally refers to an amount of a therapeutic agent that treats, alleviates, or prevents a target disease or condition, or an amount that exhibits a detectable therapeutic or preventive effect. The precise effective amount for a given subject depends on the subject's size and health, the nature and extent of the condition, and the therapeutic agent and / or combination of therapeutic agents selected for administration. Therefore, it is not useful to specify an exact effective amount in advance. However, for a given condition, the effective amount can be determined by routine experimentation, which is within the judgment of the clinician.
[0144] Unless otherwise specified, all compounds mentioned in this application are intended to include all possible optical isomers, such as single chiral compounds, or mixtures of various chiral compounds (i.e., racemates). In all compounds of this application, each chiral carbon atom may optionally be in the R configuration or the S configuration, or a mixture of the R and S configurations.
[0145] In the present application, the term "compound of the present application" generally refers to the compound of the present application. The term also includes various crystal forms, pharmaceutically acceptable salts, hydrates or solvates of the compound of the present application.
[0146] When a trade name is used herein, the trade name is intended to include the trade name product formulation, its corresponding generic drug, and the active pharmaceutical ingredient of the trade name product.
[0147] Pharmaceutical compositions and methods of administration
[0148] Since the compounds of the present invention have excellent tumor cell proliferation inhibitory activity, the compounds of the present invention and their various crystal forms, pharmaceutically acceptable inorganic or organic salts, hydrates or solvates, and pharmaceutical compositions containing the compounds of the present invention as the main active ingredient can be used to prevent and / or treat (stabilize, alleviate or cure) diseases associated with tumor cell proliferation.
[0149] The pharmaceutical compositions of the present invention comprise a safe and effective amount of a compound of the present invention and a pharmaceutically acceptable excipient or carrier. "Safe and effective amount" means an amount of the compound sufficient to significantly improve the condition without causing serious side effects. Typically, the pharmaceutical composition contains 1-2000 mg of the compound of the present invention per dose, more preferably 1-200 mg of the compound of the present invention per dose. Preferably, "one dose" is one capsule or tablet, or a unit dose of an injectable formulation.
[0150] "Pharmaceutically acceptable carrier" refers to: one or more compatible solid or liquid fillers or gel substances, which are suitable for human use and must have sufficient purity and sufficiently low toxicity. "Compatibility" here means that the components in the composition can be mixed with the compound of the present invention and with each other without significantly reducing the efficacy of the compound. Some examples of pharmaceutically acceptable carriers include cellulose and its derivatives (such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerol, mannitol, sorbitol, etc.), emulsifiers (such as ), wetting agents (such as sodium lauryl sulfate), colorants, flavorings, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.
[0151] There is no particular limitation on the administration of the compound or pharmaceutical composition of the present invention. Representative administration methods include (but are not limited to): oral administration, parenteral administration (intravenous administration, intramuscular administration, or subcutaneous administration).
[0152] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) fillers or extenders, for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid; (b) binders, for example, hydroxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose, and acacia; (c) humectants, for example, glycerol; (d) disintegrants, for example, agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) solubilizers, for example, paraffin; (f) absorption accelerators, for example, quaternary ammonium compounds; (g) wetting agents, for example, cetyl alcohol and glyceryl monostearate; (h) adsorbents, for example, kaolin; and (i) lubricants, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents.
[0153] Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared using coatings and shell materials, such as enteric coatings and other materials known in the art. They may contain opacifying agents, and the release of the active compound or compounds in such compositions can be delayed in a certain portion of the digestive tract. Examples of useful encapsulating components are polymeric substances and waxes. If desired, the active compound can also be microencapsulated with one or more of the above-mentioned excipients.
[0154] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the active compound, the liquid dosage form may contain an inert diluent conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropyl alcohol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butylene glycol, dimethylformamide, and oils, particularly cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil, or mixtures thereof.
[0155] Besides such inert diluents, the composition may also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
[0156] Suspensions, in addition to the active compounds, may contain suspending agents such as, for example, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances.
[0157] Compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.
[0158] The compounds of the present invention may be administered alone or in combination with other pharmaceutically acceptable therapeutic agents.
[0159] When administered in combination, the pharmaceutical composition may also include one or more (2, 3, 4, or more) other pharmaceutically acceptable therapeutic agents. One or more (2, 3, 4, or more) of the other pharmaceutically acceptable therapeutic agents may be used simultaneously, separately, or sequentially with the compound of the present invention to prevent and / or treat cytokine and / or interferon-mediated diseases.
[0160] When using a pharmaceutical composition, a safe and effective amount of the compound of the present invention is administered to a mammal (e.g., a human) in need of treatment, wherein the dosage is a pharmaceutically effective dosage. For a 60 kg human, the daily dosage is generally 1 to 2000 mg, preferably 1 to 500 mg. Of course, the specific dosage will also take into account factors such as the route of administration and the patient's health condition, all of which are within the skill of a skilled physician.
[0161] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the invention. The experimental methods in the following examples, for which specific conditions are not specified, are generally based on conventional conditions or the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are calculated by weight.
[0162] In the following examples, the structures of the compounds were determined by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). - 6 The unit of ppm is given. NMR measurements were performed using a Bruker AVANCE-400 NMR spectrometer. The solvents used were deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), and deuterated methanol (CD3OD), and tetramethylsilane (TMS) was used as the internal standard.
[0163] SHIMADZU LC system (chromatographic column: CSH TM Prep-C18, 19*150mm, liquid handler LH-40, pump LC-20AP, detector SPD-20A, system controller CBM-20A, solvent system: acetonitrile and 0.05% trifluoroacetic acid aqueous solution).
[0164] LC / MS spectra of the compounds were obtained using LC / MS (Agilent Technologies 1200 Series). LC / MS conditions were as follows (run time 10 minutes):
[0165] Acidic conditions: A: 0.05% trifluoroacetic acid in water; B: 0.05% trifluoroacetic acid in acetonitrile;
[0166] Alkaline conditions: A: 0.05% NH3·H2O aqueous solution; B: acetonitrile
[0167] Neutral conditions: A: 10 mM NH4OAC in water; B: acetonitrile
[0168] Unless otherwise specified, in the following examples, intermediates and final compounds were purified by silica gel column chromatography or by using CSH TM Prep-C18 (5 μm, OBD TM 19*150mm) column or XBridgeTM Prep Phenyl (5μm, OBD TM 30*100 mm) was purified by preparative HPLC on a reverse phase column.
[0169] Silica gel column chromatography generally uses Yantai Huanghai Silica Gel 200-300 mesh silica gel as the carrier.
[0170] The CombiFlash rapid preparation instrument used was Combiflash Rf200 (TELEDYNE ISCO).
[0171] Thin layer chromatography (TLC) silica gel plates use Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plates. The specifications of the silica gel plates used in thin layer chromatography detection products are 0.15mm~0.2mm, and the specifications used in thin layer chromatography separation and purification products are 0.4mm~0.5mm.
[0172] The known starting materials of the present invention can be synthesized by methods known in the art, or can be purchased from companies such as ABCR GmbH & Co. KG, Acros Organics, Aldrich Chemical Company, Accela ChemBio Inc, and Darui Chemicals.
[0173] Abbreviations: MeOH: methanol; DIEA: N,N-diisopropylethylamine; DMAP: 4-dimethylaminopyridine; DCM: dichloromethane; Dioxane: 1,4-dioxane; EA: ethyl acetate; Conc.HCl: concentrated hydrochloric acid; DMF: dimethylformamide; AcOH: acetic acid; DMA: dimethylacetamide; Xantphos: 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene; DCE: 1,2-dichloroethane; BH3: borane; Boc2O: tert-butyl carbonate; t-BuLi: tert-butyl lithium; DMF-DMA: 1,1-dimethoxy-N,N-dimethyl-methylamine; PPA: polyphosphoric acid; NaHMDS: sodium bis(trimethylsilyl)amide; POCl3: phosphorus oxychloride; Pd / C: palladium on carbon; CAN: acetonitrile; EtOH: ethanol; t-butyl nitrite: tert-butyl nitrite; pyrrolidine: pyrrolidine; toluene: toluene; TsOH: p-toluenesulfonic acid; acrylamide: prop-2-enamide; THF: tetrahydrofuran; LDA: lithium diisopropylamide; LAH: lithium aluminum hydride; Pd2(dba)3: tris(dibenzylideneacetone)dipalladium; PMB: p-methoxybenzyl; Xphos: 2-dicyclohexylphosphino-2,4,6-triisopropylbiphenyl; H2: hydrogen; Pd(dppf)Cl2: [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride; t-B uOK: potassium tert-butoxide; K2CO3: potassium carbonate; HCOONH4: ammonium formate; LiHMDS: lithium bis(trimethylsilyl)amide; Urea: urea; n-BuLi: n-butyllithium; MsCl: methanesulfonyl chloride; Dppf: bis(diphenylphosphinoferrocene); Et3N: triethylamine; AcCl: acetyl chloride; NaH: sodium hydride; TFA: trifluoroacetic acid; SOCl2: thionyl chloride; NBS: N-bromosuccinimide; NCS: N-chlorosuccinimide; 1,4-Dioxane: 1,4-dioxane; K3PO4: potassium phosphate; RuPhos Pd G2: chloro(2-dicyclohexylphosphino-2,6-di-isopropoxy-1,1-biphenyl)(2-amino-1,1-biphenyl-2-yl)palladium(II); MTBE: methyl tert-butyl ether.
[0174] Intermediate Int.A
[0175] 2-(Bis(4-methoxybenzyl)amino)-4-(butylamino)pyridin[4,3-d]pyrimidin-5(6H)-one
[0176] Step 1: Preparation of methyl 4-(butylamino)-2-chloro-6-methylpyrimidine-5-carboxylate (Int. A-1)
[0177] 2,4-Dichloro-6-methylpyrimidine-5-carboxylic acid methyl ester (10 g, 45.2 mmol) and n-butylamine (3.6 g, 49.8 mmol) were dissolved in DCM (100 ml) and DIEA (8.8 g, 67.9 mmol) was added with stirring at 0 degrees. The reaction mixture was stirred at 0 degrees for 3 hours. The reaction mixture was poured into 10% potassium bicarbonate ice water and extracted with ethyl acetate. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give a crude product. The crude product was purified by silica gel column chromatography to give a colorless oily substance, 4-(butylamino)-2-chloro-6-methylpyrimidine-5-carboxylic acid methyl ester (11.0 g, 95%). MS: 258.1 [M+H] +
[0178] Step 2: Preparation of methyl 2-(bis(4-methoxybenzyl)amino)-4-(butylamino)-6-methylpyrimidine-5-carboxylate (Int. A-2)
[0179] Methyl 4-(butylamino)-2-chloro-6-methylpyrimidine-5-carboxylate (11.0 g, 42.8 mmol) and bis(4-methoxybenzyl)amine (13.2 g, 51.4 mmol) were dissolved in acetonitrile (100 ml). KCO (8.9 g, 64.2 mmol) was added with stirring at 0°C. The reaction mixture was stirred at 70°C for 13 hours. The reaction mixture was poured into ice water and extracted with ethyl acetate. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography to obtain methyl 2-(bis(4-methoxybenzyl)amino)-4-(butylamino)-6-methylpyrimidine-5-carboxylate (18.4 g, 90%) as a yellow solid. MS: 479.3 [M+H] +
[0180] Step 3: Preparation of 2-(bis(4-methoxybenzyl)amino)-4-(butylamino)pyridin[4,3-d]pyrimidin-5(6H)-one (Int. A)
[0181] Methyl 2-(bis(4-methoxybenzyl)amino)-4-(butylamino)-6-methylpyrimidine-5-carboxylate (23 g, 48.1 mmol) and 1,3,5-triazine (4.68 g, 57.7 mmol) were dissolved in DMSO (150 mL). Potassium tert-butoxide (8.09 g, 72.1 mmol) was added with stirring at 80°C. The reaction mixture was stirred at 80°C for 2 hours. The reaction mixture was poured into ice water and extracted with ethyl acetate. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography to yield 2-(bis(4-methoxybenzyl)amino)-4-(butylamino)pyridin[4,3-d]pyrimidin-5(6H)-one (17.0 g, 74.7%) as a yellow solid. MS: 474.2 [M+H] +
[0182] Intermediate Int.B
[0183] (R)-Pentan-2-amine hydrochloride
[0184] Step 1: Preparation of (R,E)-2-methyl-N-(2-pentylidene)propane-2-sulfoxide amide (Intermediate Int. B-1)
[0185] Pentan-2-one (10 g, 116 mmol) was dissolved in EtOAc (200 ml). (R)-2-methylpropane-2-sulfoxide amide (14 g, 116 mmol) and tetraisopropyl titanate (66 g, 233 mmol) were added sequentially to the reaction mixture under stirring at 10°C. The reaction mixture was stirred at 10°C for 15 hours. The reaction mixture was poured into ice water and extracted with ethyl acetate. The organic phase was washed with water and saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography to obtain Intermediate Int.B-1 (7.0 g, 32%) as a colorless oil. MS: 190.2 [M+H] +
[0186] Step 2: Preparation of (R)-2-methyl-N-((R)-pentan-2-yl)propane-2-sulfoxide amide (Intermediate Int. B-2)
[0187] Intermediate Int.B-1 (7.0 g, 37 mmol) was dissolved in THF (100 mL). Sodium borohydride (2.1 g, 55.6 mmol) was added to the reaction mixture under stirring at -70°C. The reaction mixture was stirred at 20°C for 2 hours. The reaction mixture was poured into ice water to quench the reaction, and then extracted with ethyl acetate. The organic phase was washed with water and saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography to obtain Intermediate Int.B-2 (3.5 g, 49%) as a colorless oil. MS: 192.2 [M+H] +
[0188] Step 3: Preparation of (R)-pentane-2-amine hydrochloride (Intermediate Int. B)
[0189] Intermediate Int.B-2 (3.5 g, 18.3 mmol) was stirred in a 4N 1,4-dioxane hydrochloric acid solution (20 mL) at 20°C for 12 hours. The reaction mixture was concentrated and evaporated to dryness to obtain a crude product, which was then washed with diethyl ether to afford Intermediate Int.B (2.0 g, 90%) as a white solid.
[0190] Intermediate Int.C
[0191] (R)-2-(Bis(4-methoxybenzyl)amino)-4-(pentan-2-ylamino)pyridinyl[4,3-d]pyrimidin-5(6H)-one
[0192] Synthesis of Intermediate Int.C: Referring to Intermediate Int.A, Intermediate Int.C was prepared by using Int.B instead of n-butylamine. MS: 502.2 [M+H] +
[0193] Intermediate Int.D
[0194] (S)-2-(bis(4-methoxybenzyl)amino)-4-(1-hydroxypentan-2-yl)amino)pyridin[4,3-d]pyrimidin-5(6H)-one
[0195] The synthesis of intermediate Int.D was based on intermediate Int.A, and intermediate Int.D was prepared by using (S)-2-aminopentane-1-ol instead of n-butylamine. MS: 504.2 [M+H] +
[0196] Intermediate Int.E
[0197] 4-(Butylamino)pyrido[4,3-d]pyrimidin-5(6H)-one
[0198] Synthesis of Intermediate Int.E: Referring to Intermediate Int.A, Intermediate Int.E was prepared by using 4-chloro-6-methylpyrimidine-5-carboxylic acid methyl ester instead of 2,4-dichloro-6-methylpyrimidine-5-carboxylic acid methyl ester. MS: 219.2 [M+H] +
[0199] Intermediate Int.F
[0200] Step 1: Preparation of intermediate Int.F-1
[0201] A solution of 4-(aminomethyl)cyclohexane-1-carboxylic acid (2.51 g, 15.96 mmol) and 2,5-dioxopyrrolidin-1-yl 6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoate (2.46 g, 7.98 mmol) in acetic acid (20 ml) was stirred at 20°C for 16 hours. The reaction mixture was concentrated and evaporated to dryness, then extracted with dichloromethane. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to yield a crude product, which was purified by silica gel column chromatography to yield Intermediate Int.F-1 (0.95 g, 34%). MS: 351.2 [M+H] +
[0202] Step 2: Preparation of intermediate Int.F
[0203] A solution of EDC (193 mg, 1.005 mmol), 1-hydroxypyrrolidine-2,5-dione (108 mg, 0.942 mmol), and Intermediate Int.F-1 (220 mg, 0.628 mmol) in dichloromethane (20 mL) was stirred at 20°C for 16 hours. The reaction mixture was quenched by pouring into ice water and extracted with dichloromethane. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography to yield Intermediate Int.F (220 mg, 89%). MS: 448.2 [M+H] +
[0204] Intermediate Int.G1
[0205] The synthesis of intermediate Int.G1-2 was prepared by referring to intermediate Int.D, using 4-methoxybenzylamine instead of bis(4-methoxybenzyl)amine to obtain intermediate Int.G1-2. MS: 384.3 [M+H] + .
[0206] Synthesis of Intermediate Int.G1 Referring to Intermediate I-1-1, Intermediate Int.G1 was prepared by using 4-(chloromethyl)-3-methoxybenzaldehyde instead of methyl 4-(bromomethyl)benzoate and Intermediate Int.G1-2 instead of Intermediate Int.A. MS: 532.3 [M+H] + .
[0207] Intermediate Int.G2
[0208] The synthesis of intermediate Int.G2 was based on intermediate Int.G1. Intermediate Int.C-1 was used instead of intermediate Int.D-1 to prepare intermediate Int.G2. MS: 516.3 [M+H] + .
[0209] Intermediate Int.G3
[0210] Step 1: Preparation of intermediate Int.G3-1
[0211] Methyl 2,4-dichloro-6-methylpyrimidine-5-carboxylate (500 mg, 2.262 mmol) and pentane-2-amine (237 mg, 2.71 mmol) were dissolved in DCM (10 mL). DIEA (351 mg, 2.71 mmol) was added with stirring at 0°C. The reaction mixture was stirred at 0°C for 2 hours. The reaction mixture was poured into 10% potassium bicarbonate ice water and extracted with ethyl acetate. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography to obtain methyl 2-chloro-4-methyl-6-(pentane-2-ylamino)pyrimidine-5-carboxylate (560 mg, 91%) as a yellow solid. MS: 272.1 [M+H] +
[0212] Step 2: Preparation of intermediate Int.G3-2
[0213] Methyl 2-chloro-4-methyl-6-(pentan-2-ylamino)pyrimidine-5-carboxylate (560 mg, 2.061 mmol) and bis(4-methoxybenzyl)amine (636 mg, 2.473 mmol) were dissolved in DMSO (10 ml). DIEA (400 mg, 3.09 mmol) was added with stirring at 0°C. The reaction mixture was stirred at 100°C for 2 hours. The reaction mixture was poured into ice water and extracted with ethyl acetate. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography to obtain methyl 2-(bis(4-methoxybenzyl)amino)-4-methyl-6-(pentan-2-ylamino)pyrimidine-5-carboxylate (800 mg, 78.8%) as a yellow solid. MS: 493.3 [M+H] +
[0214] Step 3: Preparation of intermediate Int.G3-3
[0215] Methyl 2-(bis(4-methoxybenzyl)amino)-4-methyl-6-(pentan-2-ylamino)pyrimidine-5-carboxylate (800 mg, 1.624 mmol) was dissolved in 1,4-Dioxane (5 mL), and selenium dioxide (216 mg, 1.949 mmol) was added with stirring. The reaction mixture was stirred at 100°C for 12 hours. The reaction mixture was poured into ice water and extracted with ethyl acetate. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography to obtain methyl 2-(bis(4-methoxybenzyl)amino)-4-formyl-6-(pentan-2-ylamino)pyrimidine-5-carboxylate (360 mg, 43.8%) as a yellow solid. MS: 507.2 [M+H] +
[0216] Step 4: Preparation of intermediate Int.G3
[0217] Methyl 2-(bis(4-methoxybenzyl)amino)-4-formyl-6-(pentan-2-ylamino)pyrimidine-5-carboxylate (360 mg, 0.711 mmol) was dissolved in ethanol (5 mL) and hydrazine hydrate (45.5 mg, 1.421 mmol) was added with stirring at 0°C. The reaction mixture was stirred at 85°C for 1 hour. The reaction mixture was concentrated, filtered, and washed with petroleum ether / ethyl acetate to yield 2-(bis(4-methoxybenzyl)amino)-4-(pentan-2-ylamino)pyrimidin[4,5-d]pyridazin-5(6H)-one (230 mg, 66.2%) as a white solid. MS: 489.2 [M+H] +
[0218] Intermediate Int.G4
[0219] The synthesis of intermediate Int.G4 was based on intermediate Int.G3, and intermediate Int.G4 was prepared by using (S)-2-aminopentan-1-ol instead of pentane-2-amine. MS: 505.2 [M+H] + .
[0220] Example Compound I-1
[0221] Step 1: Preparation of intermediate I-1-1
[0222] 2-(Bis(4-methoxybenzyl)amino)-4-(butylamino)pyridin[4,3-d]pyrimidin-5(6H)-one (4.0 g, 8.45 mmol), methyl 4-(bromomethyl)benzoate (3.87 g, 16.89 mmol), and K2CO3 (2.335 g, 16.89 mmol) were dissolved in DMF (40 mL). The reaction mixture was stirred at 60°C for 12 hours. The reaction mixture was poured into ice water and extracted with ethyl acetate. The organic phase was washed with water and saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography to yield methyl 4-((2-(bis(4-methoxybenzyl)amino)-4-(butylamino)-5-oxopyridin[4,3-d]pyrimidin-6(5H)-yl)methyl)benzoate (4.6 g, 88%) as a yellow solid. MS:622.2[M+H] +
[0223] Step 2: Preparation of intermediate I-1-2
[0224] Intermediate I-1-1 (1.4 g, 3.54 mmol) was dissolved in THF (20 mL) and a 1.0 M solution of LAH (3.5 mL, 3.54 mmol) in tetrahydrofuran was added with stirring at 0°C. The reaction mixture was heated to 20°C and stirred for 1 hour. The reaction mixture was poured into ice water and extracted with ethyl acetate. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography to obtain Intermediate I-1-2 (1 g, 77%) as a white solid. MS: 594.2 [M+H] +
[0225] Step 3: Preparation of intermediate I-1-3
[0226] Intermediate I-1-2 (1000 mg, 2.72 mmol) was dissolved in DCM (10 mL) and thionyl chloride (486 mg, 4.08 mmol) was added with stirring at 0°C. The reaction mixture was then stirred at 20°C for 1 hour. The reaction mixture was concentrated to give Intermediate I-1-3 (1 g, 95%) as a white solid. MS: 612.2 [M+H] +
[0227] Step 4: Preparation of intermediate I-1-4
[0228] Intermediate I-1-3 (280 mg, 0.457 mmol) and piperazine (79 mg, 0.915 mmol) were dissolved in EtOH (10 mL). KCO (316 mg, 2.28 mmol) was added with stirring at 20°C. The reaction mixture was then stirred at 100°C for 1 hour. The reaction mixture was poured into ice water and extracted with ethyl acetate. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography to obtain Intermediate I-1-4 (150 mg, 61.2%) as a white solid. MS: 662.1 [M+H] + .
[0229] Step 5: Preparation of intermediate I-1-5
[0230] A solution of DIEA (58.6 mg, 0.453 mmol), Intermediate I-1-4 (100 mg, 0.151 mmol), N-tert-butyloxycarbonyl-octaethylene glycol-carboxylic acid (98 mg, 0.181 mmol), and HATU (115 mg, 0.302 mmol) in DMF (10 mL) was stirred at 20°C for 16 hours. The reaction mixture was quenched by pouring into ice water and extracted with dichloromethane. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by silica gel column chromatography to yield Intermediate I-1-5 (150 mg, 84%). MS: 1186.2 [M+H] + .
[0231] Step 6: Preparation of intermediate I-1-6
[0232] Intermediate I-1-5 (150 mg, 0.127 mmol) was dissolved in trifluoroacetic acid (5 mL), and the reaction mixture was stirred at 80°C for 1 hour. The reaction mixture was concentrated and evaporated to dryness, and extracted with ethyl acetate. The organic phase was washed with saturated sodium bicarbonate solution and saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to afford Intermediate I-1-6 (107 mg, 99%) as a yellow solid. MS: 845.3 [M+H] + .
[0233] Step 7: Preparation of Compound I-1
[0234] A solution of Intermediate I-1-6 (107 mg, 0.127 mmol) and Intermediate Int.F (60 mg, 0.13 mmol) in DMF (5 mL) was stirred at 20°C for 0.5 hours. The reaction mixture was quenched by pouring into ice water and extracted with dichloromethane. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by Prep-HPLC to yield Compound I-1 (11.0 mg, 7%) as a white solid. MS: 1177.5 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ9.38(t,J=5.5Hz,1H),7.73-7.66(m,3H),7.23(q,J=7.9Hz,4H), 6.99(s,2H),6.61(s,2H),6.07(d,J=8.0Hz,1H),5.02(s,2H),3.64-3.34(m,40H),3.15( q,J=5.9Hz,2H),2.85(t,J=6.3Hz,2H),2.52(q,J=6.7Hz,2H),2.32-2.24(m,4H),2.03–1 .98(m,2H),1.72-1.63(m,4H),1.58-1.42(m,6H),1.38–1.04(m,10H),0.94–0.75(m,5H).
[0235] Example Compound I-3
[0236] Step 1: Preparation of intermediate I-3-1
[0237] Synthesis of Intermediate I-3-1 Referring to Intermediate I-1-1, Intermediate I-3-1-1 was used instead of methyl 4-(bromomethyl)-3-methoxybenzoate to prepare Intermediate I-3-1. MS: 920.3 [M+H] + .
[0238] Step 2: Preparation of intermediate I-3-2
[0239] Synthesis of Intermediate I-3-2 Reference compound I-1-6 was prepared by using Intermediate I-3-1 instead of Intermediate I-1-5 to obtain Intermediate I-3-2. MS: 580.3 [M+H] + .
[0240] Step 3: Preparation of intermediate I-3-3
[0241] A solution of DIEA (1.77 g, 13.69 mmol), Intermediate I-3-2 (1.26 g, 1.36 mmol), and Intermediate Int.F (687 mg, 2.05 mmol) in acetonitrile (25 mL) was stirred at 20°C for 16 hours. The reaction mixture was quenched by pouring into ice water and extracted with dichloromethane. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography to yield Intermediate I-3-3 (730 mg, 66%). MS: 799.2 [M+H] + .
[0242] Step 4: Preparation of intermediate I-3-4
[0243] Synthesis of Intermediate I-3-4: Refer to Intermediate I-3-3. Intermediate I-3-3 is used instead of Intermediate I-3-3-1, and Intermediate I-3-4-1 is used instead of Intermediate I-3-2 to prepare Intermediate I-3-4. MS: 577.3 [M+2H] + / 2.
[0244] Step 5: Preparation of intermediate I-3-5
[0245] Synthesis of Intermediate I-3-5: Refer to Intermediate I-3-2 and use Intermediate I-3-4 instead of Intermediate I-3-1 to prepare Intermediate I-3-5. MS: 527.3 [M+2H] + / 2.
[0246] Step 6: Preparation of Compound I-3
[0247] The synthesis of compound I-3 was carried out by referring to intermediate I-3-3. Compound I-3 was prepared by using intermediate I-3-5 instead of intermediate I-3-2 and intermediate I-3-5-1 instead of intermediate I-3-3-1. MS: 692.6 [M+2H] + / 2.
[0248] Example Compound I-6
[0249] Synthesis of Intermediate I-6-3: Refer to Intermediate I-1-4 and use Intermediate Int.C instead of Intermediate Int.A to prepare Intermediate I-6-3. MS: 807.3 [M+H] + .
[0250] Synthesis of Intermediate I-6-4: Refer to Intermediate I-1-6 and use Intermediate I-6-3 instead of Intermediate I-1-5 to prepare Intermediate I-6-4. MS: 466.3 [M+H] + . 1H NMR (400MHz, DMSO-d6) δ9.58 (s, 1H), 7.79 (d, J = 7.5Hz, 1H), 7.23 (s, 2H), 7.0 8–6.92(m,3H),6.25(d,J=7.5Hz,1H),5.12–4.91(m,2H),4.27–4.13(m,1H), 3.85(s,3H),2.96(s,5H),2.63(s,3H),1.53–1.44(m,2H),1.34–1.26(m,2H),1.14(d,J=6.5Hz,3H),0.86(t,J=7.2Hz,3H).
[0251] Synthesis of Compound I-6 Referring to Compound I-1, Compound I-6 was prepared by using Intermediate I-6-4 instead of Intermediate I-1-4. MS: 611.2 [M+2H] + / 2.
[0252] Example Compound I-7
[0253] The synthesis of intermediate I-7-3 was prepared by referring to intermediate I-6-4 and using intermediate Int.D instead of intermediate Int.C. MS: 482.3 [M+H] + .
[0254] A solution of DIEA (29 mg, 0.244 mmol), intermediate Int.X1 (60.7 mg, 0.082 mmol), and intermediate I-7-3 (36 mg, 0.075 mmol) in DMF (10 mL) was stirred at 20°C for 1 hour. The reaction mixture was extracted with dichloromethane; the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to yield a crude product. The crude product was purified by Prep-HPLC to yield compound I-7 (36.6 mg, 45%). MS: 540.2 [M+2H] + / 2.1H NMR (400MHz, DMSO-d6) δ10.02(s,1H),9.40(d,J=8.6Hz,1H),8.33(s,1H),8.12-8.07(m,2H),7.82(d,J=8.6Hz,1H),7.57(t,J=8.3 Hz,3H),7.27(d,J=8.1Hz,1H),7.24-7.12(m,1H),6.97(d,J=16.9Hz,2H),6.91–6.79(m,3H),6.55(s,2H),6.11–5.94(m,2H),5.43 (s,2H),4.98-4.87(m,4H),4.42-4.30(m,2H),4.24-4.12(m,2H),3.82(s,3H),3.46-3.25(m,8H),3.07-2.87(m,2H),2.94(s,3H), 2.31(s,4H),2.23–2.08(m,2H),2.03–1.89(m,1H),1.75-1.38(m,8H),1.36-1.12(m,6H),1.05(d,J=6.6Hz,1H),0.89-0.81(m,8H).
[0255] Example Compound I-8
[0256] Synthesis of Compound I-8 Referring to Compound I-7, Compound I-8 was prepared by using Intermediate I-6-4 instead of Intermediate I-7-3. MS: 533.2 [M+2H] + / 2. 1H NMR (400MHz, DMSO-d6) δ10.04(s,1H),9.35(d,J=8.3Hz,1H),8.39(s,1H),8.12(t,J=9.0Hz,3H),7.84(d,J=8.7Hz,1H),7.62(d,J=9.1Hz,2H),7.3 1(d,J=8.2Hz,2H),7.01(d,J=14.8Hz,2H),6.87(t,J=9.0Hz,4H),6.61(s ,1H),6.10(d,J=7.5Hz,1H),6.04(s,1H),5.45(s,1H),5.05–4.91(m,4H), 4.41(s,1H),4.23(d,J=7.7Hz,2H),3.86(s,3H),3.48(s,2H),3.40(s,6H ),3.07–2.96(m,2H),2.36(s,4H),2.18(t,J=7.9Hz,2H),2.12(s,1H),2. 01(s,1H),1.68(d,J=36.5Hz,2H),1.51(s,6H),1.39–1.33(m,2H),1.23( d, J=7.9Hz, 2H), 1.17 (d, J=6.5Hz, 3H), 0.89 (dq, J=11.6, 6.7, 6.0Hz, 9H).
[0257] Example Compound I-9
[0258] Step 1: Preparation of intermediate I-9-1
[0259] A solution of p-toluenesulfonyl chloride (448 mg, 2.35 mmol), tert-butyl (20-hydroxy-3,6,9,12,15,18-hexaoxyethyl)carbamate (500 mg, 1.18 mmol), and pyridine (279 mg, 3.53 mmol) in dichloromethane (8 mL) was stirred at 20°C for 16 hours. The reaction mixture was quenched by pouring into ice water and extracted with dichloromethane. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography to yield Intermediate I-9-1 (150 mg, 22%). MS: 602.5 [M+Na] + .
[0260] Step 2: Preparation of intermediate I-9-2
[0261] A solution of potassium iodide (13.19 mg, 0.079 mmol), potassium carbonate (32.9 mg, 0.238 mmol), intermediate I-9-1 (69.1 mg, 0.119 mmol), and intermediate I-6-4 (37 mg, 0.079 mmol) in acetonitrile (3 ml) was microwaved at 120°C for 15 minutes. The reaction mixture was quenched by pouring into ice water and extracted with dichloromethane. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography to obtain intermediate I-9-2 (65 mg, 94%). MS: 437.5 [M+2H] + / 2.
[0262] Step 3: Preparation of intermediate I-9-3
[0263] A solution of trifluoroacetic acid (7.4 g, 0.802 mmol) and intermediate I-9-2 (70 mg, 0.08 mmol) in dichloromethane (10 mL) was stirred at 20°C for 15 minutes. The reaction mixture was concentrated to give the crude product intermediate I-9-3 (62 mg, 99%). MS: 773.7 [M+H] + .
[0264] Step 4: Preparation of Compound I-9
[0265] A solution of DIEA (104 mg, 0.244 mmol), 2,5-dioxopyrrolidin-1-yl 6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-ylhexanoate (49 mg, 0.16 mmol) and intermediate I-9-3 (60 mg, 0.08 mmol) in DMF (10 ml) was stirred at 20 degrees for 16 hours. The reaction mixture was extracted with dichloromethane; the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by Prep-HPLC to obtain compound I-9 (10.2 mg, 13%). MS: 484.0 [M+2H] + / 2. 1H NMR (400MHz, DMSO-d6) δ9.31(d,J=8.2Hz,1H),7.80(s,1H),7.54(d,J=7.6Hz,1H),6.96(d,J=22.4Hz, 2H),6.85(d,J=7.6Hz,1H),6.80(d,J=7.4Hz,1H),6.55(s,2H),6.06(d,J=7.6Hz,1H),4.93(d,J=11.2H z,2H),4.24-4.16(m,1H),3.81(s,3H),3.55-3.25(m,37H),3.16(d,J=6.1Hz,2H),2.43(t,J=6.2Hz,2H ), 2.02(t,J=7.3Hz,2H),1.52–1.41(m,4H),1.30(s,2H),1.13(d,J=6.6Hz,3H),0.87(t,J=7.3Hz,3H).
[0266] Example Compound I-10
[0267] The synthesis of compound I-10 was prepared by referring to compound I-9 and using intermediate I-7-3 instead of intermediate I-9-3 to obtain compound I-10. MS: 675.5 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ9.39(s,1H),8.28(s,2H),7.59–7.51(m,1H),7.03–6.92(m,2H),6.84(d,J=12.0Hz,2H),6.53(s,2H),6.05(d,J=6.5H z,1H),4.93(d,J=14.1Hz,2H),4.17(s,2H),3.81(s,3H),3.70-3.20(M,10H),2.31-2.24(m,5H),1.756-1.05(m,10H),0.86(q,J=6.2Hz,3H).
[0268] Example Compound I-13
[0269] Step 1: Preparation of intermediate I-13-1
[0270] A solution of tert-butyl (26-amino-3,6,9,12,15,18,21,24-octaoxahexacosadecanoyl)carbamate (102 mg, 0.2 mmol), acetic acid (24 mg, 0.4 mmol), and Intermediate Int.G2 (103 mg, 0.2 mmol) in methanol (8 mL) was stirred at 20°C for 10 minutes. Sodium acetate borohydride (127 mg, 0.6 mmol) was then added to the reaction mixture, and the mixture was stirred at 20°C for 16 hours. The reaction mixture was quenched by pouring into ice water and extracted with dichloromethane. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by silica gel column chromatography to yield Intermediate I-13-1 (150 mg, 74%). MS: 507.1 [M+2H] + / 2.
[0271] Step 2: Preparation of intermediate I-13-2
[0272] Synthesis of Intermediate I-13-2: Referring to Intermediate I-13-1, Intermediate I-13-2 was prepared by using paraformaldehyde instead of Intermediate Int.G and Intermediate I-13-1 instead of tert-butyl (26-amino-3,6,9,12,15,18,21,24-octaoxahexacosyl)carbamate. MS: 514.3 [M+2H] + / 2.
[0273] Step 3: Preparation of intermediate I-13-3
[0274] Synthesis of Intermediate I-13-3: Refer to Intermediate I-1-6 and use Intermediate I-13-2 instead of Intermediate I-1-5 to prepare Intermediate I-13-3. MS: 404.3 [M+2H] + / 2.
[0275] Step 4: Preparation of Compound I-13
[0276] A solution of DIEA (80 mg, 0.62 mmol), 2,5-dioxopyrrolidin-1-yl 3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanoate (33 mg, 0.124 mmol), and intermediate I-13-3 (50 mg, 0.062 mmol) in acetonitrile (10 mL) was stirred at 0°C for 1 hour. The reaction mixture was extracted with dichloromethane; the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give a crude product. The crude product was purified by Prep-HPLC to give compound I-9 (10.2 mg, 13%). MS: 479.5 [M+2H] + / 2. 1H NMR(400MHz,DMSO-d6)δ9.32(d,J=8.1Hz,1H),8.19(s,1H),7.99(s,1H),7.55(d,J=7.7Hz,1H) ,6.97(d,J=7.8Hz,2H),6.83(q,J=8.2,7.8Hz,2H),6.56(s,2H),6.06(d,J=7.6Hz,1H),4.94(d ,J=10.6Hz,2H),4.24-4.16(m,1H),3.81(s,3H),3.62-3.12(m,40H),2.32(t,J=7.5Hz,2H),2. 16(s,3H),1.53-1.41(m,2H),1.37-1.26(m,2H),1.13(d,J=6.5Hz,3H),0.87(t,J=7.4Hz,3H).
[0277] Example Compound I-14
[0278] Step 1: Preparation of intermediate I-14-1
[0279] Synthesis of Intermediate I-14-1: Refer to Intermediate I-1-6 and use Intermediate I-13-1 instead of Intermediate I-1-5 to prepare Intermediate I-14-1. MS: 397.3 [M+2H] + / 2.
[0280] Step 2: Preparation of Compound I-14
[0281] Synthesis of Compound I-14 Referring to Compound I-13, Compound I-14 was prepared by using Intermediate I-14-1 instead of Intermediate I-13-3. MS: 556.5 [M+2H] + / 2. 1H NMR (400MHz, DMSO-d6) δ9.31(d,J=8.0Hz,1H),7.99(s,1H),7.53(d,J=6.2Hz,1H),6.97–6.80(m,4H),6.71(t,J= 10.5Hz,1H),6.55(s,2H),6.06(d,J=7.4Hz,1H),5.04–4.84(m,2H),4.53(d,J=23.6Hz,2H),4.28–4.13(m,1H),3. 81(d,J=9.1Hz,2H),3.69-3.55(m,4H),3.53–3.25(m,36H),3.13(q,J=6.0Hz,2H),2.78-2.68(m,1H),2.64-2.54( m,1H),2.32(t,J=7.2Hz,2H),1.55–1.39(m,2H),1.38–1.26(m,2H),1.13(d,J=6.5Hz,3H),0.87(t,J=7.2Hz,3H).
[0282] Example Compound I-15
[0283] A solution of sodium bicarbonate (52.1 mg, 0.62 mmol), methyl 2,5-dioxo-2,5-dihydro-1H-pyrrole-1-carboxylate (19.2 mg, 0.124 mmol), and intermediate I-13-3 (50 mg, 0.062 mmol) in tetrahydrofuran (10 mL) was stirred at 0°C for 60 minutes. The reaction mixture was filtered and concentrated to obtain a crude product, which was purified by Prep-HPLC to yield compound I-15 (8.4 mg, 15%). MS: 453.1 [M+2H] + / 2. 1 H NMR (400MHz, DMSO-d6) δ8.00(s,1H),7.79(s,1H),7.47(d,J=7.7Hz,1H),7.11(d,J=7 .7Hz,1H),7.04(s,1H),6.99(d,J=1.7Hz,3H),6.87(s,1H),6.39(s,1H),5.05-4.96( m,2H),4.24(s,1H),3.83(s,3H),3.72(s,2H),3.64–3.34(m,40H),3.19–2.82(m,4H) ,2.02(t,J=7.6Hz,2H),1.67–1.40(m,4H),1.37–1.11(m,4H),0.88(t,J=7.3Hz,3H).
[0284] Example Compound I-17
[0285] Synthesis of Compound I-17: Referring to Compound I-13, Compound I-17 was prepared by using Intermediate Int.G2 instead of Intermediate I-13-1. MS: 695.55 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ9.30(d,J=8.0Hz,1H),7.55(d,J=7.7Hz,1H),7.00(d,J=5.4Hz,2H),6 .85(s,2H),6.72(d,J=7.9Hz,1H),6.57(s,2H),6.05(d,J=7.5Hz,1H),4.99–4.88(m,2H),4.4 6(s,1H),3.81(d,J=7.8Hz,3H),3.53–3.40(m,16H),2.90(s,2H),2.64–2.57(m,2H),2.02–1. 93(m,H),1.49–1.43(m,2H),1.32–1.27(m,2H),1.12(d,J=6.4Hz,3H),0.86(t,J=7.4Hz,3H).
[0286] Example Compound I-18
[0287] The synthesis of compound I-18 was prepared by referring to compound I-7 and using 2,5-dioxopyrrolidin-1-yl 3-(2-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethoxy)ethoxy)ethoxy)propanoate instead of intermediate Int.X1. MS: 383.4 [M+2H] + / 2. 1 H NMR (400MHz, DMSO-d6) δ9.39(d,J=8.6Hz,1H),8.35(s,1H),7.56(d,J=7.4Hz,1H),7.00(d ,J=5.1Hz,2H),6.96(s,1H),6.85(q,J=7.6Hz,2H),6.54(s,2H),6.06(d,J=7.4Hz,1H),4. 94(q,J=15.3Hz,2H),4.19(s,1H),3.82(s,4H),3.62-3.20(m,25H),3.48(dd,J=13.8,7.6 Hz, 16H), 2.56-2.51 (m, 2H), 2.36-2.25 (m, 2H), 1.35-1.26 (m, 2H), 0.87 (t, J = 7.2Hz, 3H).
[0288] Example Compound I-19
[0289] Step 1: Preparation of intermediate I-19-1
[0290] A solution of N-tert-butyloxycarbonyl-hexaethylene glycol-acetaldehyde (98 mg, 0.233 mmol), acetic acid (19.95 mg, 0.332 mmol), and Intermediate I-7-3 (80 mg, 0.166 mmol) in dichloromethane (8 mL) was stirred at 20°C for 10 minutes. Sodium acetate borohydride (106 mg, 0.498 mmol) was then added to the reaction mixture, and the mixture was stirred at 20°C for 16 hours. The reaction mixture was quenched by pouring into ice water and extracted with dichloromethane. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by silica gel column chromatography to yield Intermediate I-19-1 (75 mg, 51%). MS: 445.5 [M+2H]. + / 2.
[0291] Step 2: Preparation of Compound I-19
[0292] Synthesis of Compound I-19 Referring to Compound I-9, Compound I-19 was prepared by using Intermediate I-19-1 instead of Intermediate I-9-2. MS: 492.0 [M+2H] + / 2. 1 H NMR (400MHz, DMSO-d6) δ9.32(d,J=8.2Hz,1H),8.33(s,1H),7.55(d,J=7.5Hz,1H),6.96(s,1H) ,6.83(q,J=7.8Hz,2H),6.57(s,2H),6.06(d,J=8.0Hz,1H),6.01(d,J=1.6Hz,1H),5.02–4.86( m,2H),4.27–4.13(m,2H),3.81(s,3H),3.55-3.27(m,34H),3.24(s,2H),2.94-2.87(m,1H),2. 16(s,3H),1.52-1.42(m,2H),1.38-1.26(m,2H),1.13(d,J=6.4Hz,3H),0.87(t,J=7.4Hz,3H).
[0293] Example Compound I-20
[0294] Step 1: Preparation of intermediate I-20-1
[0295] A solution of cuprous bromide (190 mg, 1.325 mmol), 1-azido-2-(2-(2-bromoethoxy)ethane)ethane (260 mg, 1.092 mmol), and Intermediate I-20-1-01 (340 mg, 1.262 mmol) in DMF (3 mL) and water (3 mL) was stirred at 20°C for 60 minutes. Sodium cyanoborohydride (44.2 mg, 0.704 mmol) was then added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to yield a crude product, which was purified by silica gel column chromatography to yield Intermediate I-20-1 (450 mg, 81%). MS: 507.3 [M+H] + .
[0296] Step 2: Preparation of compound I-20
[0297] Synthesis of Compound I-20: Referring to Compound I-9, Compound I-20 was prepared by using Intermediate I-20-1 instead of Intermediate I-9-1 and Intermediate I-7-3 instead of Intermediate I-6-4. MS: 901.97 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ
[0298] 9.39(d,J=8.5Hz,1H),8.24(s,2H),7.85(t,J=5.6Hz,1H),7.82(s,1H),7.55(d,J=7.6Hz,1H),6.99(d,J=1.5Hz,2H),6.93(s,1H),6 .86(d,J=7.6Hz,1H),6.80(d,J=7.6Hz,1H),6.54(s,1H),6.05(d,J=6.8Hz,1H),4.95(t,J=14.8Hz,2H),4.47–4.43(m,2H),4.18(s, 2H),3.81(d,J=1.5Hz,3H),3.77(s,2H),3.48–3.44(m,12H),3.30–3.23(m,6H),2.72(d,J=7.5Hz,2H),2.41(s,2H),2.32(s,2H),2. 01(d,J=7.3Hz,2H),1.56(s,1H),1.45(t,J=7.6Hz,6H),1.29(d,J=6.2Hz,2H),1.09(dd,J=41.6,7.3Hz,2H),0.86(d,J=7.6Hz,3H).
[0299] Example Compound I-21
[0300] The synthesis of compound I-21 was based on compound I-19. Compound I-21 was prepared by using N-tert-butyloxycarbonyl-octaethylene glycol-acetaldehyde instead of N-tert-butyloxycarbonyl-hexaethylene glycol-acetaldehyde. MS: 515.1 [M+2H] + / 2. 1 H NMR (400MHz, DMSO-d6) δ9.48 (s, 1H), 8.02–7.97 (m, 1H), 7.64 (s, 1H), 6.99 (d, J = 2.1Hz, 2H), 6.93 (s, 1H), 6.86(s,1H),6.64(s,1H),6.52(s,1H),6.13(s,1H),5.32(s,1H),4.96(dd,J=24.3,15.1Hz,2H),4.80(s,1 H),3.83(s,3H),3.64–3.37(m,36H),3.17–3.12(m,4H),2.63(d,J=30.8Hz,4H),2.32(t,J=7.9Hz,4H),2. 08(s,1H),2.02–1.96(m,2H),1.63–1.53(m,2H),1.49–1.42(m,2H),1.32–1.28(m,2H),0.89–0.85(m,3H).
[0301] Example Compound I-22
[0302] Step 1: Preparation of intermediate I-22-1
[0303] The synthesis of intermediate I-22-1 was prepared by referring to intermediate I-13-3 and replacing tert-butyl (26-amino-3,6,9,12,15,18,21,24-octaoxahexacosyl)carbamate with dimethylamine. MS: 425.1 [M+H] + .
[0304] Step 2: Preparation of intermediate I-22-2
[0305] A solution of thionyl chloride (23.76 mg, 0.2 mmol) and 6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-N-((S)-1-(((S)-1-((4-(hydroxymethyl)phenyl)amino)-1-oxo-5-ureidopentan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)hexanamide (104 mg, 0.182 mmol) in dichloromethane (8 ml) was stirred at 20 degrees for 60 minutes. The reaction mixture was then concentrated to give the crude intermediate I-22-2 (107 mg, 99%). MS: 591.3 [M+H]+ .
[0306] Step 3: Preparation of Compound I-22
[0307] A solution of DIEA (22.83 mg, 0.177 mmol), intermediate I-22-1 (75 mg, 0.177 mmol), sodium iodide (53 mg, 0.353 mmol), and intermediate I-22-2 (115 mg, 0.194 mmol) in DMF (5 mL) was stirred at 80°C for 16 hours. The reaction mixture was filtered and concentrated to give the crude product, which was purified by Prep-HPLC to give compound I-22 (8.4 mg, 4.3%). MS: 490.5 [M+2H] + / 2. 1 H NMR (400MHz, DMSO-d6) δ10.33(s,1H),9.26(s,1H),8.39(s,2H),7.83(s,1H),7.75(d,J=7.7Hz,2H),7.58(d,J=7.5Hz,1H) ,7.49(d,J=8.5Hz,2H),7.22(s,2H),7.06-7.14(m,1H),6.99(d,J=3.7Hz,2H),6.61(s,2H),6.16-6.07(m,2H),5.00(d,J=1 1.7Hz,2H),4.49(d,J=16.1Hz,4H),4.40-4.32(m,1H),4.24-4.14(m,1H),3.87(s,3H),3.05-2.93(m,4H),2.84(s,6H),2.2 0-1.90(m,6H),1.52-1.39(m,10H),1.34-1.28(m,2H),1.13(d,J=6.4Hz,6H),0.96(d,J=6.6Hz,3H),0.87(t,J=7.3Hz,3H).
[0308] Example Compound I-24
[0309] Synthesis of Compound I-24 Referring to Compound I-22, Compound I-24 was prepared by using Intermediate I-7-3 instead of Intermediate I-22-1. MS: 526.1 [M+2H] + / 2. 1H NMR (400MHz, DMSO-d6) δ10.47(s,2H),9.39(d,J=8.6Hz,1H),8.39(d,J=22.0 Hz,3H),7.92(d,J=9.6Hz,1H),7.74(d,J=8.0Hz,2H),7.56(d,J=7.4Hz,1H), 7.46(d,J=8.2Hz,2H),7.01–6.93(m,2H),6.91(d,J=7.7Hz,1H),6.84(d,J=7 .8Hz,1H),6.55(s,2H),6.33(s,1H),6.07(dd,J=7.4,2.6Hz,1H),5.53(s,2H ),4.95(q,J=15.5Hz,2H),4.55(s,2H),4.39(d,J=19.6Hz,1H),4.27–3.92(m ,8H),3.83(d,J=2.6Hz,3H),3.59(s,2H),3.45(dd,J=17.0,7.2Hz,2H),3.38 –3.33(m,1H),3.28(d,J=11.3Hz,1H),3.03–2.79(m,6H),2.65(s,2H),2.14( dt,J=15.0,8.8Hz,2H),1.97(s,1H),1.73-1.15(m,10H),1.03–0.74(m,9H).
[0310] Example Compound I-25
[0311] Synthesis of Compound I-25 Referring to Compound I-15, Compound I-25 was prepared by using Intermediate I-19-2 instead of Intermediate I-13-3. MS: 444.5 [M+2H] + / 2. 1 H NMR (400MHz, DMSO-d6) δ9.39(d,J=8.4Hz,1H),8.29(s,1H),7.55(d,J=7.4Hz,1H),7.23(s,1H),6.93(s,1H),6.90–6.76(m,2H),6.55(s,2H),6.09– 5.98(m,2H),4.93(d,J=14.9Hz,3H),4.18(s,1H),3.81(s,3H),3.59–3.20(m,34H),2.91(t,J=5.3Hz, 2H), 2.43 (t, J = 5.7Hz, 2H), 2.33 (s, 2H), 2.02–1.93 (m, 2H), 1.66–1.27 (m, 4H), 0.87 (t, J = 7.5Hz, 3H).
[0312] Example Compound I-26
[0313] The synthesis of compound I-26 was based on compound I-19. Compound I-26 was prepared by using N-tert-butyloxycarbonyl-tetraethylene glycol-acetaldehyde instead of N-tert-butyloxycarbonyl-hexaethylene glycol-acetaldehyde. MS: 895.1 [M+H] + . 1 H NMR(400MHz, DMSO-d6)δ9.48(s,3H),8.13(d,J=1.9Hz,1H),8.00(s,1H),7.63(s,1H),7.01–6.83(m,5H), 6.52(s,1H),6.12(s,2H),5.31(s,1H),4.96(dd,J=24.0,14.8Hz,2H),4.80(s,1H),4.20(s,1H),3.83(s,3 H),3.58(t,J=7.8Hz,3H),3.51–3.46(m,20H),2.67(s,2H),2.58(s,2H),2.32(t,J=7.3Hz,4H),2.08(d,J =1.5Hz,1H),2.03–1.94(m,3H),1.58(s,2H),1.49–1.39(m,3H),1.31(d,J=4.6Hz,2H),0.90–0.82(m,3H).
[0314] Example Compound I-27
[0315] Step 1: Preparation of intermediate I-27-2
[0316] The synthesis of intermediate I-27-2 was based on intermediate I-26-1. Intermediate I-27-2 was prepared by using N-methyl-2-hydroxyethylamine instead of intermediate I-7-3. MS: 455.5 [M+H] + .
[0317] Step 2: Preparation of intermediate I-27-3
[0318] A solution of Intermediate I-27-2 (240 mg, 0.528 mmol), methyl (2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)acetamido)acetate (388 mg, 1.056 mmol), and sodium hydroxide (63.4 mg, 1.584 mmol) in tetrahydrofuran (10 ml) was stirred at 20°C for 3 hours. Ice water was then added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography to yield Intermediate I-27-3 (130 mg, 32%). MS: 382.4 [M+2H] + / 2.
[0319] Step 3: Preparation of intermediate I-27-4
[0320] A solution of intermediate I-27-3 (125 mg, 0.155 mmol) and diethylamine (1400 mg, 19.14 mmol) in dichloromethane (5 mL) was stirred at 0°C for 0.5 hours. The reaction mixture was then concentrated to give the crude intermediate I-27-4 (90 mg, 99%). MS: 541.5 [M+H] + .
[0321] Step 4: Preparation of intermediate I-27-5
[0322] A solution of Intermediate I-27-4 (60 mg, 0.111 mmol), (((9H-fluoren-9-yl)methoxy)carbonyl)glycylglycyla-L-phenylalanine (69.6 mg, 0.139 mmol), and 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium-4-ammonium chloride (46.1 mg, 0.166 mmol) in DMF (10 mL) was stirred at 0°C for 16 hours. The reaction mixture was then purified by silica gel column chromatography to yield Intermediate I-27-5 (40 mg, 35%). MS: 513.0 [M+2H] + / 2.
[0323] Step 5: Preparation of intermediate I-27-6
[0324] Synthesis of Intermediate I-27-6: Refer to Intermediate I-27-4 and use Intermediate I-27-5 instead of Intermediate I-27-3 to prepare Intermediate I-27-6. MS: 402 [M+2H] + / 2.
[0325] Step 6: Preparation of Compound I-27
[0326] The synthesis of compound I-27 was carried out by referring to intermediate I-27-5. Compound I-27 was prepared by using intermediate I-27-6 instead of intermediate I-27-4. MS: 498.5 [M+2H] + / 2. 1 H NMR (400MHz, DMSO-d6) δ9.35(s,1H),8.26(s,1H),8.08(s,2H),7.99(s,1H),7.56(d,J=7.6Hz,1H),7.26–7.09(m ,5H),7.01–6.92(m,3H),6.82(s,2H),5.02–4.85(m,2H),4.69(s,1H),4.44(d,J=24.3Hz,1H),3.81(s,3H),3.74 -3.62(m,4H),3.60-3.44(m,8H),3.00(d,J=13.3Hz,1H),2.91(s,1H),2.83–2.70(m,4H),2.39(t,J=6.4Hz,2H), 2.15(s,3H),2.12–2.05(m,2H),2.04-1.92(m,1H),1.55-1.40(m,8H),1.20-1.03(m,5H),0.86(t,J=7.5Hz,3H).
[0327] Example Compound I-28
[0328] Step 1: Preparation of intermediate I-28-1
[0329] The synthesis of intermediate I-28-1 was based on intermediate I-7-3. Intermediate I-28-1 was prepared by using 4-methylpiperazine instead of piperazine. MS: 496.1 [M+H] + .
[0330] Step 2: Preparation of intermediate I-28-2
[0331] A solution of Intermediate I-28-1 (80 mg, 0.161 mmol), pyridine (192 mg, 2.42 mmol), and 4-nitrophenylcarbonyl chloride (325 mg, 1.614 mmol) in dichloromethane (8 mL) was stirred at 20°C for 16 hours. The reaction mixture was then poured into ice water to quench the mixture and extracted with dichloromethane. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to yield the crude product, which was purified by silica gel column chromatography to yield Intermediate I-28-2 (20 mg, 19%). MS: 331.4 [M+2H] + / 2.
[0332] Step 3: Preparation of intermediate I-28-3
[0333] Synthesis of Intermediate I-28-3: Refer to Intermediate I-7 and use tert-butyl methyl (2-(methylamino)ethyl)carbamate instead of Intermediate I-7-3 to prepare Intermediate I-28-3. MS: 809.7 [M+Na] + .
[0334] Step 4: Preparation of intermediate I-28-3
[0335] The synthesis of compound I-28 was performed by referring to compound I-9 and replacing intermediate I-9-2 with intermediate I-28-3 to obtain compound I-28. MS: 605.1 [M+2H] + / 2. 1 H NMR(400MHz,DMSO-d6)δ9.96(s,1H),9.45(s,1H),8.12(s,1H),8.05(s,1H),7.81(s,1H),7.56(s,2 H),7.23(s,2H),6.98(s,1H),6.94(s,1H),6.81(s,1H),6.62(s,2H),6.08(s,1H),5.98(s,1H),5.4 1(s,2H),5.01-4.85(m,4H),4.40(s,2H),4.16(s,1H),4.04(s,2H)3.80(s,3H),3.15-2.85(m,14H) ,2.80-2.66(m,4H),2.60(s,3H),2.21-1.90(m,4H),1.61-1.11(m,10H),0.90-82(d,J=13.2Hz,3H).
[0336] Example Compound I-29
[0337] Step 1: Preparation of intermediate I-29-2
[0338] The synthesis of intermediate I-29-2 was based on intermediate I-13-3. Intermediate I-29-2 was prepared by replacing tert-butyl (26-amino-3,6,9,12,15,18,21,24-octaoxahexacosyl)carbamate with tert-butyl methyl (piperidin-4-yl)carbamate. MS: 494.4 [M+H] + .
[0339] Step 2: Preparation of intermediate I-29-2
[0340] Synthesis of Compound I-29 Referring to Compound I-26, Compound I-29 was prepared by using Intermediate I-29-2 instead of Intermediate I-7-3. MS: 907.2 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ9.31(d,J=8.3Hz,1H),7.80(s,1H),7.56(d,J=7.6Hz,1H),6.99(d,J=1.2Hz,2H),6.95(s,1 H),6.88–6.81(m,2H),6.59(s,2H),6.07(d,J=7.3Hz,1H),4.94(q,J=15.4Hz,2H),3.82(s,3H),3.53–3.45(m,22H) ,3.37(dd,J=5.6,2.0Hz,8H),3.16(d,J=6.0Hz,2H),2.89(d,J=7.6Hz,2H),2.44(d,J=12.8Hz,2H),2.02(t,J=7.4H z,3H),1.75(d,J=11.6Hz,2H),1.48–1.43(m,6H),1.33–1.28(m,2H),1.14(d,J=6.6Hz,3H),0.87(t,J=7.3Hz,3H).
[0341] Example Compound I-30
[0342] The synthesis of compound I-30 was performed with reference to compound I-9, by using intermediate I-6-4 instead of intermediate I-9-3 and 2,5-dioxopyrrolidin-1-yl 4-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-methyl)cyclohexane-1-carboxylate instead of 2,5-dioxopyrrolidin-1-yl 6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl hexanoate to prepare compound I-30. MS: 685.9 [M+H] + . 1H NMR (400MHz, DMSO-d6) δ9.31(d,J=7.4Hz,1H),7.55(d,J=8.1Hz,1H),6.99(d,J=1.8Hz,2H),6.95(s,1H),6. 84(q,J=7.8Hz,2H),6.56(s,2H),6.06(d,J=8.3Hz,1H),5.00–4.88(m,2H),4.20(s,1H),3.82(d,J=1.8Hz,2 H),3.44(s,3H),3.30–3.21(m,6H),2.49–2.45(m,5H),2.29(d,J=24.2Hz,4H),1.96(s,1H),1.60(t,J=11.3 Hz,3H),1.51–1.44(m,2H),1.35–1.27(m,2H),1.13(d,J=6.3Hz,2H),1.01–0.93(m,2H),0.91–0.83(m,3H).
[0343] Example Compound I-31
[0344] The synthesis of compound I-31 was performed by referring to compound I-9 and replacing intermediate I-9-3 with intermediate I-6-4 to obtain compound I-31. MS: 659.9 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ9.42(d,J=8.1Hz,1H),7.62(d,J=7.4Hz,1H),6.99(d,J=1.6Hz,2H),6.97(s,1H),6.9 0(d,J=7.8Hz,1H),6.84(d,J=7.8Hz,1H),6.78(s,2H),6.12(d,J=7.5Hz,1H),5.02–4.90(m,2H),4.34–4.04( m,2H),3.82(s,2H),3.50(s,3H),3.25–3.16(m,4H),2.35(d,J=20.5Hz,4H),2.24(t,J=7.4Hz,2H),1.98(s,1 H), 1.46 (q, J = 7.5Hz, 6H), 1.35–1.27 (m, 2H), 1.22–1.18 (m, 2H), 1.14 (d, J = 6.4Hz, 3H), 0.87 (t, J = 7.1Hz, 3H).
[0345] Example Compound I-32
[0346] Step 1: Preparation of intermediate I-32-1
[0347] A solution of tert-butyl (6-bromohexyl)carbamate (79 mg, 0.28 mmol), potassium carbonate (77 mg, 0.56 mmol), and intermediate I-6-4 (87 mg, 0.187 mmol) in DMF (3 mL) was microwaved at 100°C for 0.5 h. The reaction mixture was quenched by pouring into ice water and extracted with dichloromethane. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude product, which was purified by silica gel column chromatography to give intermediate I-32-1 (90 mg, 72%). MS: 333.5 [M+2H] + / 2.
[0348] Step 2: Preparation of compound I-32
[0349] Synthesis of Compound I-32 Referring to Compound I-14, Compound I-32 was prepared by using Intermediate I-32-1 instead of Intermediate I-13-1. MS: 323.2 [M+2H] + / 2. 1 H NMR (400MHz, DMSO-d6) δ9.31 (d, J=8.2Hz, 1H), 8.23 (s, 2H),7.61–7.49(m,1H),7.04–6.90(m,2H),6.89–6.76(m,2H),6.57(s,2 H),6.10–6.02(m,1H),4.93(d,J=11.2Hz,2H),4.19(d,J=7.9Hz,1H),3.8 1(s,3H),3.41(s,2H),3.39–3.32(m,2H),2.34(s,8H),2.22(d,J=7.3Hz, 2H),1.52-1.16(m,12H),1.15-1.07(m,3H),0.87(td,J=7.3,1.9Hz,3H).
[0350] Example Compound I-33
[0351] Step 1: Preparation of intermediate I-33-1
[0352] A solution of DIEA (96 mg, 0.741 mmol), 4-(tert-butyl)-1-(2,5-dioxopyrrolidin-1-yl)(tert-butoxycarbonyl)-L-aspartate (115 mg, 0.296 mmol), and Intermediate I-6-4 (115 mg, 0.247 mmol) in DMF (10 mL) was stirred at 20°C for 16 hours. The reaction mixture was quenched by pouring into ice water and extracted with dichloromethane. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by silica gel column chromatography to yield Intermediate I-33-1 (98 mg, 54%). MS: 737.6 [M+H] + .
[0353] Step 2: Preparation of compound I-33
[0354] Synthesis of Compound I-33 Referring to Compound I-9, Compound I-33 was prepared by using Intermediate I-33-1 instead of Intermediate I-9-2. MS: 590.4 [M+2H] + / 2. 1 H NMR (400MHz, DMSO-d6) δ9.97(s,1H),9.55(s,1H),8.05(d,J=7.4Hz,1H),7.78(d,J=8.5Hz,1H),7.72(d,J=8.5Hz,1H),7.59(d,J=8.1Hz,2H) ,7.25(d,J=8.1Hz,2H),7.06(s,1H),6.99(d,J=2.1Hz,2H),6.93(d,J=8.1Hz,1H),6.86(t,J=4.7Hz,1H),6.18(d,J=7.6Hz,1H),5.97(s,1H) ,5.40(s,2H),5.06-4.89(m,3H),4.72(d,J=7.5Hz,1H),4.37(s,1H),4.26–4.11(m,2H),3.82(d,J=2.1Hz,3H),3.65-3.15(m,10H),3.11–2. 85(m,3H),2.76–2.63(m,1H),2.46–2.34(m,2H),2.13(dq,J=14.6,7.5 Hz, 2H), 1.95 (d, J = 7.0Hz, 1H), 1.74-1.10 (m, 16H), 0.95-0.73 (m, 9H).
[0355] Example Compound I-34
[0356] Step 1: Preparation of intermediate I-34-2
[0357] The synthesis of intermediate I-34-2 was prepared by referring to intermediate I-13-3, and using (2-(piperazin-1-yl)ethyl)carbamic acid tert-butyl ester instead of (26-amino-3,6,9,12,15,18,21,24-octaoxahexacosyl)carbamic acid tert-butyl ester to obtain intermediate I-34-2. MS: 509.5 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ10.47(s,1H),9.98(d,J=8.4Hz,1H),8.27(s,1H),8.05(d,J=7 .4Hz,1H),7.77(s,2H),7.23(s,1H),7.12–7.01(m,2H),6.40(d,J=7.4Hz,1H),5.15–5 .03(m,2H),4.30–4.24(m,2H),3.85(s,3H),3.55–3.25(m,8H),2.92(s,4H),2.56(s,1 H), 1.57–1.43 (m, 2H), 1.36–1.27 (m, 2H), 1.19 (d, J = 6.5Hz, 3H), 0.88 (t, J = 7.3Hz, 3H).
[0358] Step 2: Preparation of Compound I-34
[0359] Synthesis of Compound I-34: Referring to Compound I-9, Compound I-34 was prepared by using Intermediate I-34-2 instead of Intermediate I-9-3. MS: 702.9 [M+H] + .
[0360] Example Compound I-35
[0361] Step 1: Preparation of intermediate I-35-1
[0362] Synthesis of Intermediate I-35-1 Reference compound I-9 was prepared by using glycylglycyl-L-phenylalanine instead of intermediate I-9-3 to obtain intermediate I-35-1. MS: 473.4 [M+H] + .
[0363] Step 2: Preparation of intermediate I-35-3
[0364] The synthesis of intermediate I-35-3 was prepared by referring to intermediate I-27-4 and replacing intermediate I-27-2 with intermediate I-28-1. MS: 291.9 [M+2H] + / 2.
[0365] Step 3: Preparation of compound I-35
[0366] Synthesis of Compound I-35 Referring to Compound I-27, Compound I-35 was prepared by using Intermediate I-35-3 instead of Intermediate I-27-6 and Intermediate I-35-1 instead of 6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoic acid. MS: 519.0 [M+2H] + / 2. 1 H NMR(400MHz,DMSO-d6)δ9.45(s,2H),8.25(s,2H),8.07(s,2H),7.99(s,1H),7.55(s,1 H),7.25-7.10(s,4H),6.84-6.81(m,2H),5.00-4.95(m,2H),4.79(s,1H),4.69(s,2H), 4.48(s,1H),3.80(s,3H),3.67(s,4H),3.55-3.10(m,12H),3.00(d,J=14.6Hz,2H),2. 75(s,2H),2.32(s,5H),2.10(d,J=18.6Hz,4H),1.65-1.05(m,10H),0.91-0.86(m,3H).
[0367] Example Compound I-36
[0368] Step 1: Preparation of intermediate I-36-1
[0369] A solution of DIEA (552 mg, 4.27 mmol), HATU (650 mg, 1.71 mmol), (1r,4r)-4-(((tert-butoxycarbonyl)amino)methyl)cyclohexane-1-carboxylic acid (110 mg, 0.427 mmol), and Intermediate I-6-4 (199 mg, 0.427 mmol) in DMF (8 mL) was stirred at 20°C for 1 hour. The reaction mixture was quenched by pouring into ice water and extracted with dichloromethane. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product, which was purified by silica gel column chromatography to obtain Intermediate I-36-1 (200 mg, 66.4%). MS: 706.7 [M+H] + .
[0370] Step 2: Preparation of Compound I-36
[0371] Synthesis of Compound I-36: Referring to Compound I-19, Compound I-36 was prepared by using Intermediate I-36-1 instead of Intermediate I-19-1. MS: 799.2 [M+H] + . 1H NMR(400MHz,DMSO-d6)δ9.77(s,1H),8.13(s,1H),7.81(s,1H),7.69(s,1H),6.99(s,2H),6.87(s,1 H),6.64(s,1H),6.50(s,2H),6.27(s,1H),5.02(d,J=9.2Hz,2H),4.24(s,2H),3.83(s,3H),3.50–3. 32(m,9H),2.86(s,2H),2.66(s,1H),2.48–2.46(m,4H),2.32(s,1H),2.01(d,J=7.2Hz,2H),1.66(t ,J=16.3Hz,4H),1.50–1.40(m,6H),1.35–1.27(m,6H),1.16(d,J=5.5Hz,3H),0.87(t,J=7.1Hz,3H).
[0372] Example Compound I-37
[0373] Synthesis of Compound I-37 Referring to Compound I-13, Compound I-37 was prepared by using Intermediate I-36-2 instead of Intermediate I-13-3. MS: 756.9 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ9.31(d,J=7.8Hz,1H),8.23(s,1H),7.88(s,1H),7.55(d,J=7.6Hz,1H),6.99(s,2H),6.96(s,1H) ,6.87–6.81(m,1H),6.56(s,2H),6.06(d,J=7.2Hz,1H),4.94(d,J=11.1Hz,2H),4.23–4.18(m,2H),3.82(s,3H),3.58(t,J =7.3Hz,2H),3.46–3.43(m,6H),2.98(s,1H),2.83(t,J=6.6Hz,2H),2.59(s,1H),2.34–2.32(m,4H),2.28–2.27(m,1H),2 .02–1.96(m,2H),1.63(t,J=13.1Hz,4H),1.49–1.47(m,2H),1.34–1.27(m,4H),1.13(d,J=5.4Hz,3H),0.90–0.85(m,3H).
[0374] Example Compound I-38
[0375] Synthesis of Compound I-38 Referring to Compound I-35, Compound I-38 was prepared by using Intermediate I-34-2 instead of Intermediate I-35-3. MS: 519.0 [M+2H] + / 2. 1 H NMR (400MHz, DMSO-d6) δ9.31(d,J=8.0Hz,1H),8.48(s,1H),8.19(s,1H),8.04(s,1H),7.55(d,J=7.3Hz,1H),7.37(d ,J=7.4Hz,2H),7.16(dd,J=18.6,11.8Hz,4H),6.95(d,J=17.5Hz,2H),6.84(t,J=9.2Hz,2H),6.59(s,2H),6.06(d,J= 7.6Hz,1H),4.93(d,J=11.7Hz,2H),4.26-4.17(m,2H),4.13-4.01(mz,3H),3.81(s,3H),3.74–3.55(m,10H),3.45-3 .10(m,10H),2.40-2.30(m,2H),2.15-2.05(m,2H),1.60-1.25(m,10H),1.13(d,J=6.4Hz,3H),0.87(t,J=7.5Hz,3H).
[0376] Example Compound I-39
[0377] Step 1: Preparation of intermediate I-39-1
[0378] A solution of ethylenediamine (8.06 g, 134 mmol) and 6-aminoisobenzofuran-1(3H)-one (4 g, 26.8 mmol) in methanol (100 mL) was stirred at 20°C for 40 hours. The reaction mixture was filtered and concentrated to give the crude intermediate I-39-1 (5.6 g, 99%). MS: 210.4 [M+H] + .
[0379] Step 2: Preparation of intermediate I-39-2
[0380] A solution of allyl chloroformate (3 g, 24.85 mmol) in tetrahydrofuran (10 mL) was slowly added dropwise to a solution of intermediate I-39-1 (5.2 g, 24.85 mmol) in DMF (50 mL) at 0°C with stirring. The reaction mixture was then stirred at 20°C for 16 hours. The reaction mixture was quenched by pouring into ice water and extracted with dichloromethane. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by silica gel column chromatography to yield intermediate I-39-2 (2.54 g, 35%). MS: 609.4 [2M+Na] + .
[0381] Step 3: Preparation of intermediate I-39-3
[0382] A solution of (S)-2-((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-methylbutanamide)-5-ureidopentanic acid (2 g, 4.03 mmol), ethyl 2-ethoxyquinoline-1(2H)-carboxylate (1.99 g, 8.06 mmol), and Intermediate I-39-2 (2.36 g, 8.06 mmol) in tetrahydrofuran (50 ml) was stirred at 20 degrees for 16 hours. The reaction mixture was quenched by pouring into ice water and extracted with dichloromethane. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give a crude product, which was purified by silica gel column chromatography to give Intermediate I-39-3 (2.2 g, 71%). MS: 772.5 [M+H] + .
[0383] Step 4: Preparation of intermediate I-39-4
[0384] A solution of bis(4-nitrophenyl) carbonate (1.66 g, 5.44 mmol), DIEA (1.06 g, 8.16 mmol), and Intermediate I-39-3 (2.1 g, 2.72 mmol) in DMF (30 mL) was stirred at 20°C for 16 hours. The reaction mixture was quenched by pouring into ice water and extracted with dichloromethane. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by silica gel column chromatography to yield Intermediate I-39-4 (250 mg, 9%).
[0385] Step 5: Preparation of intermediate I-39-5
[0386] A solution of Intermediate I-6-4 (100 mg, 0.215 mmol), DIEA (139 mg, 1.074 mmol), and Intermediate I-39-4 (241 mg, 0.258 mmol) in DMF (35 mL) was stirred at 20°C for 0.5 hours. The reaction mixture was quenched by pouring into ice water and extracted with dichloromethane. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography to obtain Intermediate I-39-5 (100 mg, 37%). MS: 632.6 [M+2H] + / 2.
[0387] Step 6: Preparation of intermediate I-39-6
[0388] A solution of tetrakistriphenylphosphine palladium (11 mg, 9.5 μmol), phenylsilane (137 mg, 1.27 mmol), and intermediate I-39-5 (80 mg, 0.063 mmol) in dichloromethane (5 mL) was stirred at 20°C for 2 hours. The reaction mixture was quenched by pouring into ice water and extracted with dichloromethane. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography to obtain intermediate I-39-6 (75 mg, 99%). MS: 590.6 [M+2H] + / 2.
[0389] Step 7: Preparation of intermediate I-39-7
[0390] A solution of DIEA (8.22 mg, 0.064 mmol), HATU (24.2 mg, 0.064 mmol), 2,5,8,11,14,17,20,23-octaoxahexacosa-26-carboxylic acid (26.2 mg, 0.064 mmol), and Intermediate I-39-6 (75 mg, 0.064 mmol) in DMF (5 mL) was stirred at 20°C for 16 hours. The reaction mixture was quenched by pouring into ice water and extracted with dichloromethane. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to yield the crude product, which was purified by silica gel column chromatography to yield Intermediate I-39-7 (95 mg, 95%). MS: 787.8 [M+2H] + / 2.
[0391] Step 8: Preparation of intermediate I-39-8
[0392] A solution of diethylamine (4.41 mg, 0.06 mmol) and intermediate I-39-7 (95 mg, 0.06 mmol) in dichloromethane (10 mL) was stirred at 20°C for 0.5 hours. The reaction mixture was filtered and concentrated to give the crude product, intermediate I-39-8 (80 mg, 98%). MS: 676.7 [M+2H] + / 2.
[0393] Step 9: Preparation of intermediate I-39-9
[0394] A solution of DIEA (76 mg, 0.592 mmol), intermediate I-39-8-1 (69.2 mg, 0.118 mmol), and intermediate I-39-8 (80 mg, 0.059 mmol) in DMF (10 mL) was stirred at 20°C for 0.5 hours. The reaction mixture was concentrated to give the crude product, intermediate I-39-9 (95 mg, 99%). MS: 533.9 [M+3H] + / 3.
[0395] Step 10: Preparation of Compound I-39
[0396] Synthesis of Compound I-39: Referring to Compound I-19, Compound I-39 was prepared by using Intermediate I-39-9 instead of Intermediate I-19-2. MS: 897.2 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ9.30(s,1H),8.48(s,1H),8.19(s,1H),8.04(s,2H),7.55(d,J=7.2Hz,1H),7.37(d,J=7.4Hz,4 H),7.12(d,J=7.2Hz,3H),6.95(d,J=17.5Hz,2H),6.88–6.78(m,2H),6.59(s,5H),6.06(d,J=7.7Hz,1H),5.02-4.88(m ,2H),4.26-4.16(m,2H),4.13-4.01(m,4H),3.81(s,3H),3.71–3.58(m,10H),3.50-3.20(m,56H),2.42-2.31(m,4H),2 .30-2.20(m,2H),2.17-2.05(m,4H),2.04-1.95(m,1H),1.55-1.28(m,12H),1.13(d,J=6.4Hz,3H),0.95-0.80(m,9H).
[0397] Example Compound I-41
[0398] Step 1: Preparation of intermediate I-41-1
[0399] Synthesis of Intermediate I-41-1 Referring to Intermediate I-36-1, Intermediate I-41-1 was prepared by using 3-((2-(tert-butoxycarbonyl)amino)ethoxy)propionic acid instead of (1r,4r)-4-(((tert-butoxycarbonyl)amino)methyl)cyclohexane-1-carboxylic acid. MS: 681.6 [M+H] + .
[0400] Step 2: Preparation of Compound I-41
[0401] Synthesis of Compound I-41: Referring to Compound I-32, Compound I-41 was prepared by using Intermediate I-41-1 instead of Intermediate I-32-2. MS: 661.4 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ9.32(d,J=8.3Hz,1H),8.30(s,2H),7.57(d,J=7.6Hz,1H),7.02(s,1H),6.97( s,1H),6.90–6.82(m,2H),6.60(s,1H),6.07(d,J=7.5Hz,1H),4.95(q,J=15.3Hz,2H),4.27–4.15(m,2H ),3.83(d,J=3.6Hz,3H),3.59–3.53(m,10H),2.46(d,J=6.6Hz,2H),2.31(d,J=19.2Hz,4H),2.04–1.97 (m,1H),1.51–1.45(m,2H),1.33(dd,J=13.7,6.8Hz,2H),1.14(d,J=6.6Hz,3H),0.88(t,J=7.3Hz,3H).
[0402] Example Compound I-42
[0403] The synthesis of compound I-42 was prepared by referring to compound I-19, using tert-butyl (2-(3-oxopropoxy)ethyl)carbamate instead of N-tert-butyloxycarbonyl-hexaethylene glycol-acetaldehyde and intermediate I-6-4 instead of intermediate I-7-3 to obtain compound I-42. MS: 647.5 [M+H] + . 1H NMR (400MHz, DMSO-d6) δ9.32(d,J=8.2Hz,1H),8.31(s,1H),7.56(d,J=7.5Hz,1H),7.03(s,1H),6.94(s,1H),6.84(q,J=7.8H z,2H),6.59(s,2H),6.07(d,J=7.5Hz,1H),4.94(q,J=15.3Hz,2H),4.21(dt,J1=14.2,J2=6.9Hz,2H),3.82(s,3H),3.55(t,J =5.7Hz,2H),3.45(t,J=5.7Hz,2H),3.35(t,J=6.4Hz,2H),2.33(dq,J1=15.3,J2=6.0,J3=4.9Hz,8H),2.21(t,J=7.3Hz,2H), 2.03–1.98(m,1H),1.54(t,J=6.9Hz,2H),1.49–1.44(m,2H),1.34–1.29(m,2H),1.14(d,J=6.5Hz,3H),0.88(t,J=7.3Hz,3H).
[0404] Example Compound I-43
[0405] Synthesis of Compound I-43 Referring to Compound I-7, Compound I-43 was prepared by using Intermediate I-17-2 instead of Intermediate I-7-3. MS: 505.2 [M+2H] + / 2. 1H NMR (400MHz, DMSO-d6) δ10.03(s,1H),9.33(d,J=8.3Hz,1H),8.13(d,J=7.6Hz,1H),7.84(d,J=8.6Hz,1H),7.70–7.55(m, 3H),7.34(d,J=9.8Hz,2H),7.02(s,2H),6.92(d,J=7.7Hz,2H),6.79(s,1H),6.61(s,2H),6.09(d,J=7.5Hz,1H),6.02(s,1 H),5.45(s,2H),5.06(s,2H),4.96(d,J=13.4Hz,2H),4.41(d,J=12.1Hz,3H),4.30–4.17(m,2H),3.79(s,3H),3.70(s,2H) ,3.04(s,2H),2.83(s,3H),2.27–2.08(m,1H),2.00(s,1H),1.80–1.17(m,15H),1.16(d,J=6.4Hz,3H),0.92–0.84(m,9H).
[0406] Example Compound I-44
[0407] Step 1: Preparation of intermediate I-44-2
[0408] The synthesis of intermediate I-44-2 was prepared by referring to intermediate I-17-2 and using intermediate Int.G1 instead of intermediate Int.G2. MS: 427.1 [M+H] + .
[0409] Step 2: Preparation of Compound I-44
[0410] Synthesis of Compound I-44: Referring to Compound I-7, Compound I-44 was prepared by using Intermediate I-44-2 instead of Intermediate I-7-3. MS: 513.2 [M+2H] + / 2. 1H NMR (400MHz, DMSO-d6) δ10.03(s,1H),9.42(d,J=8.7Hz,1H),8.30-8.04(m,1H),7.85(d,J=8.6Hz,1H),7.60(q,J=7.5,7.0Hz,3H), 7.34(d,J=10.4Hz,2H),7.01(s,2H),6.93(d,J=7.5Hz,1H),6.83(d,J=32.4Hz,2H),6.59(s,2H),6.09(d,J=7.5Hz,1H),6.03(s,1H ),5.46(s,2H),5.06(s,2H),4.96(q,J=15.3Hz,2H),4.41(d,J=11.0Hz,3H),4.28–4.15(m,2H),3.79(s,3H),3.70(s,2H),3.42–3. 35(m,2H),3.15–2.91(m,2H),2.83(s,3H),2.17(dt,J=13.8,6.7Hz,2H),2.07–1.91(m,1H),1.81-1.14(m,14H),0.97-0.80(m,9H).
[0411] Example Compound I-45
[0412] Step 1: Preparation of intermediate I-45-1
[0413] A solution of TEA (303 mg, 3 mmol), glycylglycyl-L-phenylalanine (279 mg, 1 mmol), and di-tert-butyl dicarbonate (240 mg, 1.1 mmol) in methanol (5 mL) was stirred at 20°C for 16 hours. The reaction mixture was quenched by pouring into ice water and extracted with dichloromethane. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography to yield intermediate I-39-4 (350 mg, 92%). MS: 380.4 [M+H] + .
[0414] Step 2: Preparation of intermediate I-45-4
[0415] Synthesis of Intermediate I-45-4 Reference compound I-36 was prepared by using glycine tert-butyl ester instead of intermediate I-6-4 to obtain intermediate I-45-4. MS: 530.4 [M+H] + .
[0416] Step 3: Preparation of Compound I-45
[0417] The synthesis of compound I-45 was carried out by referring to intermediate I-45-2. Compound I-45 was prepared by using intermediate I-45-4 instead of intermediate I-45-1 and intermediate I-34-2 instead of glycine tert-butyl ester. MS: 511.7 [M+2H] + / 2. 1 H NMR(400MHz, DMSO-d6)δ9.40(d,J=8.5Hz,1H),8.42(s,1H),7.56(d,J=7.5Hz,1H), 7.01(s,1H),6.94(s,1H),6.85(t,J=10.7Hz,2H),6.55(s,2H),6.06(d,J=7.7Hz,1H ),4.94(d,J=14.9Hz,2H),4.19(s,1H),3.82(s,1H),3.60-3.20(m,10H),2.33(s,4H ),2.24-2.16(m,2H),2.03-1.95(m,2H),1.53-1.26(m,10H),0.88(t,J=7.9Hz,3H).
[0418] Example Compound I-46
[0419] Step 1: Preparation of intermediate I-46-2
[0420] Synthesis of Intermediate I-46-2 Reference compound I-32 was prepared by using 6-(tert-butoxycarbonylamino)-1-hexanol instead of Intermediate I-32-1 to obtain Intermediate I-46-2. MS: 198.2 [M+H] + .
[0421] Step 2: Preparation of intermediate I-46-3
[0422] A solution of Dess-Martin (351 mg, 0.827 mmol) and intermediate I-46-2 (136 mg, 0.69 mmol) in dichloromethane (5 mL) was stirred at 20°C for 1 hour. The reaction mixture was quenched by pouring into ice water and extracted with dichloromethane. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography to obtain intermediate I-46-3 (85 mg, 63%). MS: 218.4 [M+Na] + .
[0423] Step 3: Preparation of Compound I-46
[0424] The synthesis of compound I-46 was carried out by referring to intermediate I-19-1. Compound I-46 was prepared by using intermediate I-46-3 instead of N-tert-butyloxycarbonyl-hexaethylene glycol-acetaldehyde. MS: 330.9 [M+2H] + / 2.
[0425] Example Compound I-47
[0426] Step 1: Preparation of intermediate I-47-1
[0427] Intermediate I-6-1 (2.1 g, 3.61 mmol) was dissolved in MeOH (20 mL) and 0.8 M aqueous sodium hydroxide solution (9 mL, 7.2 mmol) was added with stirring at 0°C. The reaction mixture was stirred at 50°C for 14 hours. The reaction mixture was cooled and poured into ice water. The pH value was adjusted to 4 with 1N hydrochloric acid and extracted with ethyl acetate. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography to obtain Intermediate I-47-1 (1.6 g, 85%). MS: 666.2 [M+H] +
[0428] Step 2: Preparation of intermediate I-47-2
[0429] A mixture of Intermediate I-47-1 (1.6 g, 3.1 mmol), HATU (2.3 g, 6.2 mmol), DIEA (3.2 ml), and 6-(tert-butyloxycarbonyl)-3,6-diazabicyclo[3.1.1]heptane (1.8 g, 9.3 mmol) in DMF (20 ml) was stirred at 20°C for 2 hours. The reaction mixture was then poured into ice water and extracted with ethyl acetate. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to yield a crude product, which was purified by silica gel column chromatography to yield Intermediate I-47-2 (2.7 g, 100%). MS: 846.2 [M+H] +
[0430] Step 3: Preparation of intermediate I-47-3
[0431] Synthesis of Intermediate I-47-3 Reference compound I-1-6 was used to prepare Intermediate I-47-3 by replacing Intermediate I-1-5 with Intermediate I-47-2. MS: 492.2 [M+H] + .
[0432] Step 4: Preparation of Compound I-47
[0433] Synthesis of Compound I-47 Referring to Compound I-8, Compound I-47 was prepared by using Intermediate I-47-1 instead of Intermediate I-6-4. MS: 1090.5 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ10.06(s,1H),9.33(d,J=8.2Hz,1H),8.15(d,J=7.3Hz,1H),7.86(d,J=8.6Hz,1H),7.63(dd,J=8.4,3.8Hz,3H),7.28(s,2H),7. 03(s,3H),6.94(q,J=7.7Hz,2H),6.66(s,1H),6.13(d,J=7.8Hz,1H),6.02( s,0H),5.46(s,2H),5.20–4.90(m,3H),4.41(d,J=7.4Hz,1H),4.24(dd,J=17 .2,10.8Hz,3H),4.17–3.98(m,1H),3.86(s,3H),3.58–3.23(m,16H),3.01( dt,J=28.9,7.1Hz,2H),2.16(ddt,J=21.3,14.2,7.0Hz,1H),2.07–1.90(m,1 H),1.77–1.66(m,1H),1.66–1.58(m,1H),1.57–1.41(m,8H),1.43–1.31(m, 3H), 1.29–1.19 (m, 2H), 1.17 (d, J = 6.6 Hz, 3H), 0.88 (dq, J = 13.3, 7.0 Hz, 9H).
[0434] Example Compound I-48
[0435] The synthesis of intermediate I-48-1 was prepared by referring to intermediate I-32-2, replacing tert-butyl (6-bromohexyl)carbamate with tert-butyl (2-(2-bromoethoxy)ethoxy)ethyl)carbamate and intermediate I-7-3 with intermediate I-6-4 to obtain intermediate I-48-1. MS: 613.6 [M+H] + .
[0436] Synthesis of Compound I-48: Referring to Compound I-19, Compound I-48 was prepared by using Intermediate I-48-1 instead of Intermediate I-19-2. MS: 403.9 [M+2H] + / 2. 1H NMR (400MHz, DMSO-d6) δ9.44(d,J=8.5Hz,1H),8.23(s,1H),7.87(d,J=5.8Hz,1H),7.61(d,J=7.5Hz,1H),7.0 4(s,2H),6.98(s,1H),6.94–6.83(m,2H),6.63(s,2H),6.10(d,J=7.5Hz,1H),4.98(q,J=15.3Hz,2H),4.23(s, 1H),3.86(s,4H),3.38-3.52(m,16H),3.19(q,J=5.8Hz,2H),2.52–2.32(m,8H),2.06(t,J=7.4Hz,2H),1.67–1 .57(m,1H),1.50(p,J=7.4Hz,5H),1.34(dt,J=15.7,7.8Hz,2H),1.21(q,J=8.0Hz,2H),0.91(t,J=7.3Hz,3H).
[0437] Example Compound I-50
[0438] Compound I-50 was synthesized by referring to compound I-48 and replacing intermediate Int.D with intermediate Int.G4 to obtain compound I-50. MS: 777.6 [M+H] + . 1 H NMR(400MHz, DMSO-d6)δ9.05(d,J=8.9Hz,1H),7.88–7.81(m,2H),7.29(s,4H),7.04(d,J=3.1H z,4H),5.29–5.10(m,2H),4.89(s,1H),4.28–4.15(m,1H),3.59(s,3H),3.40(tt,J=7.0,3.9Hz ,10H),3.19(q,J=5.9Hz,3H),2.78(s,6H),2.05(t,J=7.4Hz,2H),1.62(td,J=14.4,13.9,7.5H z,1H),1.49(p,J=7.4Hz,6H),1.42–1.25(m,2H),1.20(q,J=7.9Hz,2H),0.91(t,J=7.3Hz,3H).
[0439] Example Compound I-51
[0440] Synthesis of Compound I-51 Referring to Compound I-24, Compound I-51 was prepared by using Intermediate I-50-3 instead of Intermediate I-7-3. MS: 504.36 [M+2H] + / 2. 1 H NMR (400MHz, DMSO-d6) δ9.05(d,J=9.0Hz,1H),8.10(d,J=6.4Hz,1H),7.84(d,J=16. 1Hz,2H),7.57(s,1H),7.28(s,5H),7.03(s,3H),6.00(s,1H),5.44(s,2H),5.27–5. 12(m,1H),4.88(d,J=5.2Hz,1H),4.40(s,1H),4.21(s,2H),3.52(d,J=16.1Hz,4H), 3.02(s,3H),2.36(s,2H),2.25–2.07(m,2H),1.76–1.14(m,14H),0.97–0.75(m,9H).
[0441] Example Compound I-52
[0442] Synthesis of Compound I-52: Referring to Compound I-51, Compound I-51 was prepared by using Intermediate I-50-2 instead of Intermediate I-7-2. MS: 511.6 [M+2H] + / 2. 1 H NMR (400MHz, DMSO-d6) δ10.35(s,1H),9.05(d,J=8.7Hz,1H),8.57(s,1H),8.27(s,1H),7.87(s,2H),7.76(d,J=8 .1Hz,2H),7.48(d,J=8.3Hz,2H),7.30(s,5H),7.03(s,3H),6.16(s,1H),5.50(s,2H),5.21(d,J=17.6Hz,1H),4.9 1(s,1H),4.57(s,2H),4.39(s,1H),4.21(d,J=7.7Hz,2H),3.62(s,2H),3.48(d,J=18.1Hz,4H),2.97(d,J=27.1Hz ,5H),2.84(s,2H),2.67(s,2H),2.25–2.08(m,1H),1.98(d,J=6.7Hz,1H),1.81–1.14(m,16H),1.09–0.67(m,9H).
[0443] Example Compound I-53
[0444] Synthesis of Compound I-53 Referring to Compound I-7, Compound I-53 was prepared by using Intermediate I-50-3 instead of Intermediate I-7-3. MS: 526.6 [M+2H] + / 2. 1 H NMR (400MHz, DMSO-d6) δ10.02(s,1H),9.05(d,J=8.7Hz,1H),8.11(d,J=7.5Hz,1H),7.84(d,J=14.5Hz,2H),7.6 0(d,J=8.2Hz,2H),7.30(d,J=11.3Hz,5H),7.02(s,3H),6.00(s,1H),5.44(s,2H),5.29–5.09(m,1H),5.01(s,2H ),4.87(d,J=5.3Hz,1H),4.39(d,J=7.2Hz,1H),4.21(t,J=7.7Hz,2H),3.59–3.44(m,4H),3.00(dt,J=27.6,6.7H z,2H),2.32(s,3H),2.17(dt,J=14.7,7.2Hz,2H),1.98(d,J=6.8Hz,1H),1.80–1.14(m,14H),0.95–0.80(m,9H).
[0445] Preparation of Antibody-Drug Conjugates
[0446] The reaction for forming the antibody-drug conjugate of the present application is carried out under conditions sufficient to covalently bind the payload-linker compound to the antibody. Typically, the antibody is contacted with the payload-linker compound, and the four interchain disulfide bonds in the antibody are completely or partially reduced to react with the payload-linker compound. The number of drug payload molecules per ADC (also referred to as drug-antibody ratio, DAR) may be an integer or decimal from 1 to 8, for example, the drug-antibody ratio may be an integer or decimal from 1 to 2, 2 to 3, 3 to 4, 4 to 5, 5 to 6, 6 to 7, 7 to 8, preferably an antibody-drug ratio of 2 to 7, more preferably an antibody-drug ratio of 3 to 6, and most preferably an antibody-drug ratio of 4 to 5. In some example embodiments of the present invention, the drug-antibody ratio is selected from 3 to 6.
[0447] In embodiments, when used in an antibody-drug conjugate reaction, the molar equivalent ratio of payload-linker to antibody can be about 1:1, about 3:1, about 5:1, about 10:1, about 15:1, about 20:1, about 30:1, and ranges thereof, such as about 1:1 to about 30:1, about 1:1 to about 20:1, about 1:1 to about 15:1, about 1:1 to about 10:1, about 1:1 to about 5:1, about 1:1 to about 3:1, allowing for the use of excess payload-linker compound. In some embodiments of the present invention, the molar equivalent ratio of payload-linker to antibody is about 5:1 to about 20:1.
[0448] In the embodiment, when used for antibody-drug conjugate reactions, the reaction can be carried out at any suitable temperature. Typically, the reaction is carried out at a temperature of about 0°C to about 40°C. The reaction can be carried out at, for example, about 4°C, about 25°C, about 37°C, or a range, for example, 2 to 8°C. In some embodiments of the present invention, the reaction temperature is 37°C. In some embodiments of the present invention, the reaction temperature is 25°C. In some embodiments of the present invention, the reaction temperature is 2 to 8°C.
[0449] In embodiments, when used for antibody-drug conjugate reactions, the reaction can be carried out at any suitable pH. Typically, the reaction is carried out at a pH of about 4.5 to about 10. Preferably, the reaction is carried out at a pH of about 5 to about 9. More preferably, the reaction is carried out at a pH of about 7.0 to 7.2. In some embodiments of the present invention, the reaction is carried out at a pH of about 7.0 to 7.2.
[0450] In embodiments, when used for antibody-drug conjugate reactions, the reaction can be carried out for any suitable length of time. Typically, the reaction mixture is incubated under suitable conditions for about 1 minute to tens of hours. The reaction can be carried out for about 1 minute, or about 5 minutes, or about 10 minutes, or about 30 minutes, or about 1 hour, or about 2 hours, or about 4 hours, or about 8 hours, or about 12 hours, or about 24 hours, or about 48 hours. In some embodiments of the present invention, the reaction time is about 2 hours.
[0451] The reaction mixture for forming the antibody-drug conjugate may contain common reagents for antibody-drug conjugation reactions. Reaction reagents include but are not limited to the following reagents, and may contain a cosolvent (e.g., dimethyl sulfoxide, dimethylformamide, ethanol, acetone, propylene glycol, glycerol, acetic acid), a buffer (e.g., 2-morpholineethanesulfonic acid (MES), N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES), 3-morpholinepropanesulfonic acid (MOPS), phosphate buffer, histidine buffer, citrate buffer, borate buffer, acetate buffer or similar buffer), a reducing agent (e.g., tris(2-carboxyethyl)phosphine (TCEP), dithiothreitol (DTT ... Thioerythritol (DTE), 2-mercaptoethanol (BME)), surfactants (e.g., polysorbate 20, polysorbate 60, polysorbate 80, poloxamer 188), and metal chelators (e.g., ethylenediaminetetraacetic acid (EDTA), ethylene glycol diethyl ether diaminetetraacetic acid (EGTA), 2-bis(2-aminophenoxy)ethane-N, N, N', N'-tetraacetic acid (BAPTA)), buffers, cosolvents, surfactants, metal chelators, and reducing agents can be used in any suitable concentration, which can be readily determined by those skilled in the art. Typically, the concentrations of the buffers, cosolvents, surfactants, metal chelators, and reducing agents in the reaction can range from about 1 uM to about 1 M. For example, a buffer, a cosolvent, a surfactant, a chelating agent, a reducing agent can be included in the reaction mixture at a concentration of about 1 uM, or about 10 uM, or about 100 uM, or about 1 mM, or about 10 mM, or about 25 mM, or about 50 mM, or about 100 mM, or about 250 mM, or about 500 mM, or about 1 M. In some embodiments of the present invention, a cosolvent, a buffer, or a reducing agent is used.
[0452] Other reaction conditions may be used in the methods of the invention depending on the characteristics of the antibody in the antibody-drug conjugate and the chemical characteristics of the linker to which the payload is attached.
[0453] ADC preparation plan
[0454] The antibody was prepared at 1-20 mg / mL and the antibody was purified by Zeba TMSpin Desalting Columus (ThermoFisher Scientific) was used to exchange the antibody solution into a PBS buffered aqueous solution (0.01 M PBS buffer at pH 7.2). The payload-linker was dissolved in DMA at a concentration of 1-20 mg / ml. The reducing agent TCEP (5 mM) was incubated with the antibody at a ratio of (1:1 to 5:1) for 2 hours at 37°C. The payload-linker was incubated with the antibody at a ratio of (1:1 to 20:1) at room temperature or 2-8°C, and other excipients (e.g., metal chelator EDTA, L-cysteine, etc.) were optionally added for 2 hours before desalting (Zeba TM The phosphates and unreacted or excess payload-linkers were purified using Spin Desalting Columus (ThermoFisher Scientific) and stored in a histidine solution (20 mM histidine buffer at pH 5.5) at 2-8°C.
[0455] ADC concentration was measured at 280 nm using a Nanodrop (micro-volume UV-visible spectrophotometer, UV-vis). The drug-to-antibody ratio (i.e., the amount of payload attached to the antibody) was determined by HIC (hydrophobic interaction chromatography), PR-HPLC (polymer-based reversed-phase chromatography), or MALDI-TOF MS (matrix-assisted laser desorption ionization time-of-flight mass spectrometry). ADC purity was determined by SEC (size exclusion chromatography), and the amount of free drug was determined by HPLC (high-performance liquid chromatography). The purified antibody-drug conjugate was filtered through a 0.22 μm sterile filter and stored at −80°C.
[0456] The following ADC preparation process can obtain different DAR values (N a ) antibody drug conjugate.
[0457] Example ADC-II-1
[0458] The Herceptin antibody was prepared into a 20 mg / ml solution and the solution was diluted with Zeba TMUsing a Spin Desalting Columus (ThermoFisher Scientific), the antibody solution was exchanged into a PBS buffered aqueous solution (0.01 M PBS buffer, pH 7.2). TCEP (5 mM) was added at a molar ratio of 3:1 reducing agent:antibody, and the solution was incubated at 37°C for 2 hours. Compound I-1 was dissolved in DMA to prepare a 5 mg / ml stock solution, and compound I-1 (5 mg / ml) was added at a molar ratio of 7:1 compound I-1595:antibody, and the solution was incubated at 2-8°C for 2 hours. The solution was desalted and purified by exchanging it into a histidine solution (20 mM histidine buffer, pH 5.5). Antibody concentration was measured at 280 nm using a Nanodrop UV spectrophotometer. Purity was determined by SEC-HPLC. The DAR was determined to be 4.62 by PR-HPLC analysis. The antibody-drug conjugate was filtered through a 0.22 μm sterile filter and stored at -80°C to obtain the antibody-drug conjugate ADC-II-1.
[0459] Example ADC-II-3
[0460] The synthesis of ADC-II-3 was based on ADC-II-1, and ADC-II-3 was prepared by using compound I-3 instead of compound I-1. The DAR was 3.96.
[0461] Example ADC-II-6
[0462] The synthesis of ADC-II-6 was carried out with reference to ADC-II-1, and ADC-II-6 was prepared by using compound I-6 instead of compound I-1.
[0463] Example ADC-II-7
[0464] The synthesis of ADC-II-7 was based on ADC-II-1, and ADC-II-7 was prepared by using compound I-7 instead of compound I-1. The DAR was 3.44.
[0465] Example ADC-II-8
[0466] The synthesis of ADC-II-8 was carried out with reference to ADC-II-1, and ADC-II-8 was prepared by using compound I-8 instead of compound I-1.
[0467] Example ADC-II-9
[0468] The synthesis of ADC-II-9 was based on ADC-II-1, and ADC-II-9 was prepared by using compound I-9 instead of compound I-1. The DAR was 3.88.
[0469] Example ADC-II-10
[0470] The synthesis of ADC-II-10 was based on ADC-II-1, and ADC-II-10 was prepared by using compound I-10 instead of compound I-1. The DAR was 4.9.
[0471] Example ADC-II-13
[0472] The synthesis of ADC-II-13 was based on ADC-II-1, and ADC-II-13 was prepared by using compound I-13 instead of compound I-1. The DAR was 4.34.
[0473] Example ADC-II-15
[0474] The synthesis of ADC-II-15 was carried out with reference to ADC-II-1, and ADC-II-15 was prepared by using compound I-15 instead of compound I-1.
[0475] Example ADC-II-17
[0476] The synthesis of ADC-II-17 was carried out with reference to ADC-II-1, and ADC-II-17 was prepared by using compound I-17 instead of compound I-1.
[0477] Example ADC-II-18
[0478] The synthesis of ADC-II-18 was carried out with reference to ADC-II-1, and ADC-II-18 was prepared by using compound I-18 instead of compound I-1.
[0479] Example ADC-II-19
[0480] ADC-II-19 was synthesized with reference to ADC-II-1, and ADC-II-19 was prepared by using compound I-19 instead of compound I-1. The DAR was 4.32.
[0481] Example ADC-II-20
[0482] The synthesis of ADC-II-20 was based on ADC-II-1, and ADC-II-20 was prepared by using compound I-20 instead of compound I-1. The DAR was 5.31.
[0483] Example ADC-II-21
[0484] The synthesis of ADC-II-21 was carried out with reference to ADC-II-1, and ADC-II-21 was prepared by using compound I-21 instead of compound I-1.
[0485] Example ADC-II-22
[0486] The synthesis of ADC-II-22 was carried out with reference to ADC-II-1, and ADC-II-22 was prepared by using compound I-22 instead of compound I-1.
[0487] Example ADC-II-24
[0488] The synthesis of ADC-II-24 was based on ADC-II-1, and ADC-II-24 was prepared by using compound I-24 instead of compound I-1. The DAR was 4.4.
[0489] Example ADC-II-25
[0490] The synthesis of ADC-II-25 was based on ADC-II-1, and ADC-II-25 was prepared by using compound I-25 instead of compound I-1. The DAR was .
[0491] Example ADC-II-26
[0492] The synthesis of ADC-II-26 was based on ADC-II-1, and ADC-II-26 was prepared by using compound I-26 instead of compound I-1. The DAR was 4.84.
[0493] Example ADC-II-27
[0494] The synthesis of ADC-II-27 was based on ADC-II-1, and ADC-II-27 was prepared by using compound I-27 instead of compound I-1. The DAR was 4.39.
[0495] Example ADC-II-28
[0496] The synthesis of ADC-II-28 was based on ADC-II-1, and ADC-II-28 was prepared by using compound I-28 instead of compound I-1. The DAR was 4.06.
[0497] Example ADC-II-29
[0498] The synthesis of ADC-II-29 was based on ADC-II-1, and ADC-II-29 was prepared by using compound I-29 instead of compound I-1. The DAR was 4.69.
[0499] Example ADC-II-30
[0500] The synthesis of ADC-II-30 was based on ADC-II-1, and ADC-II-30 was prepared by using compound I-30 instead of compound I-1. The DAR was 4.17.
[0501] Example ADC-II-31
[0502] The synthesis of ADC-II-31 was based on ADC-II-1, and ADC-II-31 was prepared by using compound I-31 instead of compound I-1. The DAR was 4.79.
[0503] Example ADC-II-32
[0504] The synthesis of ADC-II-32 was based on ADC-II-1, and ADC-II-32 was prepared by using compound I-32 instead of compound I-1. The DAR was 4.80.
[0505] Example ADC-II-33
[0506] The synthesis of ADC-II-33 was based on ADC-II-1, and ADC-II-33 was prepared by using compound I-33 instead of compound I-1. The DAR was 3.72.
[0507] Example ADC-II-34
[0508] The synthesis of ADC-II-34 was based on ADC-II-1, and ADC-II-34 was prepared by using compound I-34 instead of compound I-1. The DAR was 4.85.
[0509] Example ADC-II-35
[0510] The synthesis of ADC-II-35 was carried out with reference to ADC-II-1, and ADC-II-35 was prepared by using compound I-35 instead of compound I-1.
[0511] Example ADC-II-36
[0512] The synthesis of ADC-II-36 was based on ADC-II-1, and ADC-II-36 was prepared by using compound I-36 instead of compound I-1. The DAR was 4.18.
[0513] Example ADC-II-37
[0514] The synthesis of ADC-II-37 was carried out with reference to ADC-II-1, and ADC-II-37 was prepared by using compound I-37 instead of compound I-1.
[0515] Example ADC-II-38
[0516] The synthesis of ADC-II-38 was carried out with reference to ADC-II-1, and ADC-II-38 was prepared by using compound I-38 instead of compound I-1.
[0517] Example ADC-II-39
[0518] The synthesis of ADC-II-39 was carried out with reference to ADC-II-1, and ADC-II-39 was prepared by using compound I-39 instead of compound I-1.
[0519] Example ADC-II-41
[0520] The synthesis of ADC-II-41 was based on ADC-II-1, and ADC-II-41 was prepared by using compound I-41 instead of compound I-1. The DAR was 4.20.
[0521] Example ADC-II-42
[0522] ADC-II-42 was synthesized with reference to ADC-II-1, and ADC-II-42 was prepared by using compound I-42 instead of compound I-1. The DAR was 3.76.
[0523] Example ADC-II-43
[0524] ADC-II-43 was synthesized with reference to ADC-II-1, and ADC-II-43 was prepared by using compound I-43 instead of compound I-1. The DAR was 3.76.
[0525] Example ADC-II-44
[0526] ADC-II-44 was synthesized with reference to ADC-II-1, and ADC-II-44 was prepared by using compound I-44 instead of compound I-1. The DAR was 4.15.
[0527] Example ADC-II-45
[0528] The synthesis of ADC-II-45 was carried out with reference to ADC-II-1, and ADC-II-45 was prepared by using compound I-45 instead of compound I-1.
[0529] Example ADC-II-46
[0530] ADC-II-46 was synthesized with reference to ADC-II-1, and ADC-II-46 was prepared by using compound I-46 instead of compound I-1. The DAR was 4.09.
[0531] Example ADC-II-47
[0532] The synthesis of ADC-II-47 was carried out with reference to ADC-II-1, and ADC-II-47 was prepared by using compound I-47 instead of compound I-1.
[0533] Example ADC-II-48
[0534] ADC-II-48 was synthesized with reference to ADC-II-1, and ADC-II-48 was prepared by using compound I-48 instead of compound I-1. The DAR was 3.92.
[0535] Example ADC-II-50
[0536] The synthesis of ADC-II-50 was based on ADC-II-1, and ADC-II-50 was prepared by using compound I-50 instead of compound I-1. The DAR was 3.40.
[0537] Example ADC-II-51
[0538] The synthesis of ADC-II-51 was based on ADC-II-1, and ADC-II-51 was prepared by using compound I-51 instead of compound I-1. The DAR was 4.30.
[0539] Example ADC-II-52
[0540] ADC-II-52 was synthesized with reference to ADC-II-1, and ADC-II-52 was prepared by using compound I-52 instead of compound I-1. The DAR was 3.88.
[0541] Example ADC-II-53
[0542] The synthesis of ADC-II-53 was based on ADC-II-1, and ADC-II-53 was prepared by using compound I-53 instead of compound I-1. The DAR was 4.03.
[0543] Example ADC-III-7
[0544] Rituximab antibody was prepared into a 10 mg / ml solution and diluted with Zeba TM Using a Spin Desalting Columus (ThermoFisher Scientific), the antibody solution was exchanged into a PBS buffered aqueous solution (0.01 M PBS buffer, pH 7.2). TCEP (5 mM) was added at a molar ratio of 2.6:1 reducing agent:antibody, and the solution was incubated at 37°C for 2 hours. Compound I-7 was dissolved in DMA to prepare a 5 mg / ml stock solution, and compound I-7 (5 mg / ml) was added at a molar ratio of 10:1 compound 4-1763:antibody, and the solution was incubated at 2-8°C for 2 hours. The solution was desalted and purified by exchanging it into a histidine solution (20 mM histidine buffer, pH 5.5). Antibody concentration was measured at 280 nm using a Nanodrop UV spectrophotometer. Purity was determined by SEC-HPLC. The DAR was determined to be 4.12 by RP-HPLC analysis. The antibody-drug conjugate was filtered through a 0.22 μm sterile filter and stored at -80°C to obtain the antibody-drug conjugate ADC-III-7.
[0545] Example ADC-III-24
[0546] The synthesis of ADC-III-24 was based on ADC-III-7, and ADC-III-24 was prepared by using compound I-24 instead of compound I-7. The DAR was 3.69.
[0547] Example ADC-III-26
[0548] The synthesis of ADC-III-26 was based on ADC-III-7, and ADC-III-26 was prepared by using compound I-26 instead of compound I-7. The DAR was 4.21.
[0549] Example ADC-III-44
[0550] ADC-III-44 was synthesized with reference to ADC-III-7, and ADC-III-44 was prepared by using compound I-44 instead of compound I-7. The DAR was 4.34.
[0551] Biological test methods
[0552] Experimental Materials:
[0553] Cells: human peripheral blood mononuclear cells (hPBMC), tumor cells (such as human breast cancer cells HCC1954, human B cell lymphoma cells SU-DHL-4, etc.)
[0554] Antibodies: Trastuzumab (Herceptin), Rituximab (Rituximab), and corresponding antibody-conjugated products, small molecules, or small molecule-linkers.
[0555] Experimental process
[0556] 1) Add 100 μL of freshly thawed hPBMCs and 50 μL of tumor cells to a 96-well plate. The cell counts per well are 2.1E+5 and 7E+4, respectively.
[0557] 2) Prepare the drug stock solution in DMSO to 10 mM. Note: The concentration can be adjusted as needed.
[0558] 3) Serial dilution of drugs:
[0559] Dilute the reference compound and test compound stock solutions 4-fold in DMSO to prepare a 4× working solution for a total of nine concentration gradients. Add 50 μL of drug-containing medium to each well of a 96-well plate, performing a nine-step concentration gradient with two replicates. Finally, add 200 μL of medium per well at a 1× compound concentration (starting concentration 1 μM). Note: The starting concentration, dilution factor, number of gradients, and number of replicates can be adjusted as needed.
[0560] 4) Place in a 37°C, 5% CO2 incubator and culture for 20-24 hours.
[0561] 5) Take 16 μL / well of the culture medium supernatant and detect the cytokine content in the supernatant using ELISA or HTRF method, including but not limited to TNF-α, IFN-γ, etc.
[0562] Calculate the half-stimulatory concentration (EC) of the drug using GraphPad Prism 50 TNF-αEC 50 (μM): A<0.05μM, B>0.05μM;
[0563] Table 3 ECs of ADCs disclosed herein that stimulate TNF-α secretion in human PBMC cells 50
[0564] It can be seen from this that the antibody-drug conjugate of the present invention can stimulate human peripheral blood mononuclear cells to produce TNF-α.
[0565] All documents mentioned in this application are incorporated herein by reference, just as if each document were incorporated herein by reference individually. It should also be understood that after reading the above teachings of the present invention, those skilled in the art may make various changes or modifications to the present invention, and that such equivalents also fall within the scope of the claims appended hereto.
Claims
1. An immunoconjugate, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or a pharmaceutically acceptable salt or hydrate thereof, wherein the immunoconjugate comprises a structure shown in Formula I: It comprises an antibody covalently linked to a divalent linker, the divalent linker covalently linked to one or more toxin D moieties, and the immunoconjugate has Formula I: Pc-[-LYD] N a (I) in: Pc is an antibody or antigen-binding fragment covalently linked to a divalent linker -LY-; N a is the average number of connections, which is a decimal or integer greater than 0; preferably an integer or decimal from 1 to 20; D is a toxin having a structure selected from the group consisting of Formula Ia, Formula Ib, Formula Ic or Formula Id, and the toxin is covalently linked to a divalent linker -LY- via an N or S atom in the molecule: in: L 11 Selected from the group consisting of -O-, -NH-, -S-, -S(=O)- or -S(=O)2-; R1 is selected from the following group: H, C 1-12 Alkyl, C 2-12 Alkenyl, C 2-12 Alkynyl, C 3-12 Cycloalkyl or 4-12 membered heterocycloalkyl; wherein said R1 may be further replaced by one or more R 1a Substituents, and the R 1a Selected from the group consisting of hydrogen, halogen, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, -NR a1 R a2 、-NHC(=O)-R a3 , one or more R a4 Substituted 5-6 membered heteroaryl, -OC(=O)R a5 、-C(=O)R a5 、-OC(=O)OR a5 、-C(=O)OR a5 ; The R a1 , R a2 , R a3 or R a4 Select from the following group: C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl; The R a5 Select from the following group: C 1-24 Alkyl, halogenated C 1-24 Alkyl, C 1-24 Heteroalkyl, wherein the heteroatom is selected from one or more of NH, N, O and S; Said R2 and R3 are independently selected from the following groups: hydrogen, halogen, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, 5-8 membered heterocyclic aryl, or 5-8 membered aryl; wherein said R2 may be further substituted by one or more substituents selected from the group consisting of halogen, hydroxyl, cyano, or amino; m is 0, 1, 2, 3, 4, 5, 6, 7 or 8; B does not exist, or B is selected from the following group: C 3-12 Cycloalkyl, 4-12 membered heterocycloalkyl, C 6-12 Aryl, 5-12 membered heteroaryl or wherein each A is independently selected from C, CH or N, and R6 and R7 together with their adjacent carbon atoms form C 4-7 Cycloalkane Base or C 4-7 Heterocycloalkylene, the C 4-7 One or more methylene groups in the cycloalkylene or 4-7 membered heterocycloalkylene groups may be independently replaced by a carbonyl group or S(═O)2; in the 4-7 membered heterocycloalkylene groups, the heteroatom is selected from N, O, and S, and the number of the heteroatoms is 1 to 3; L 12 Select from the following group: None, -(CR 1b R 1c ) p -(NR 1d ) q -、-O-、-S-、-(CR 1b R 1c ) p -C(=O)-、-(CR 1b R 1c ) p -C(=O)NH-, -(CR 1b R 1c ) p -NHC(=O)-, -S(=O)- or -S(=O)2-; wherein R 1b , R 1c Selected from the group consisting of hydrogen, halogen, C 1-6 Alkyl, C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl or C 1-6 Haloalkyl, R 1d Selected from the group consisting of hydrogen, C 1-6 Alkyl, C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, C 1-6 C substituted with halogenated alkyl or hydroxyl 1-6 Alkyl, p is 0, 1, 2, 3, 4, 5 or 6, q is 0 or 1; R4 is selected from the group consisting of hydrogen, halogen, cyano, amino, hydroxyl, C 1-12 Alkyl, C 1-12 Alkoxy, C 2-12 Alkenyl, C 2-12 Alkynyl, C 3- 12 Cycloalkyl, 4-12 membered heterocycloalkyl, C 6-12 Aryl or 5-12 membered heteroaryl; and said R4 may be optionally replaced by one or more R e Substituent substitution, where R e Selected from the group consisting of hydrogen, halogen, hydroxy, carboxylic acid, amino, C 1-6 Alkyl, one or more R e1 Substituted C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 4-12 heterocycloalkyl, C 6-12 Aryl, 5-12 membered heteroaryl, -N(R e2 R e3 )、-C(=O)OR e2 、-C(=O)NH-R e2 、-S(=O)2-R e2 ; And when L 12 is none and R 4 When H, B is selected from the following group: C 3-12 Cycloalkyl, 4-12 membered heterocycloalkyl, C 6-12 Aryl, 5-12 membered heteroaryl or wherein each A is independently selected from C, CH or N, and R6 and R7 together with their adjacent carbon atoms form C 4-7 Cycloalkylene or C 4-7 Heterocycloalkylene; R e1 Selected from the group consisting of halogen, hydroxyl; R e2 , R e3 Selected from the group consisting of hydrogen, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 C substituted with halogenated alkyl or hydroxyl 1-6 alkyl; R5 is selected from the group consisting of halogen, hydroxy, cyano, amino, C 1-6 Alkyl, C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -C(=O)OR f 、-C(=O)NH-R f 、-S(=O)2-R f ; where R f Selected from the group consisting of hydrogen, C 1-6 Alkyl, C 3-6 Cycloalkyl or C 1-6 Haloalkyl; n is 1, 2, 3, 4, 5 or 6; Wherein, each of the heterocyclic groups may be saturated or partially unsaturated (but not having an aromatic structure), and in the heterocyclic group, the heteroatom is selected from N, O, S, and the number of heteroatoms is 1, 2, 3 or 4 (preferably 1 or 2); in the heteroaryl group, the heteroatom is selected from N, O, S, and the number of heteroatoms is 1, 2 or 3.
2. The immunoconjugate according to claim 1, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or its pharmaceutically acceptable salt or hydrate, characterized in that: The divalent linker LY has a structure as shown in the following formula: -L1-L2-L3-L4-Y-; Wherein, the L1 is -SS-, R d is H, C1-C6 alkyl, C1-C6 deuterated alkyl, C3-C8 cycloalkyl or C3-C8 deuterated cycloalkyl; The L2 is a group selected from the following group: -(CHR) m1 -, optionally substituted -(CHR) m1 -C(O)NH-(CH2CH2O) n3 -(CHR) m2 -, optionally substituted -(CH2CH2O) n3 -(CHR) m2 -, optionally substituted -(CHR) m1 -C(O)NH-(CH2CH2O) n3 -(CHR) m2 -C(O)-, optionally substituted -(CHR) m1 -(CH2CH2O) n3 -(CHR) m2 -、-(CHR) m1 -C(O)-, optionally substituted -(CHR) m1 -C(O)-L4-NH(CH2CH2O) n3 -(CHR) m2 -, optionally substituted -(CHR) m1 -C(O)NH-(CHR) m1 -5-10 membered aromatic heterocycle-(CH2CH2O) n3 -(CHR) m2 -, optionally substituted -(CHR) m1 -C(O)-L4-NH-(CH2CH2O) n3 -L4-(CHR) m2 -, optionally substituted -(CHR) m1 -C(O)-L4-NH(RCH) m1 -(OCH2CH2) n3 -L4-(CHR) m2 -, optionally substituted -(CHR) m1 -C3-C9 cycloalkyl-(CHR) m2 -, optionally substituted -(CHR) m1 -C3-C9 heterocycloalkyl-(CHR) m2 -; The L4 is an optionally substituted group selected from the group consisting of: a chemical bond, Among them, the R a and R b Each is independently selected from the following group: hydrogen, optionally substituted C1-C4 alkyl, optionally substituted C1-C4 deuterated alkyl, CH2COOH; The R 101 Selected from the group consisting of hydrogen, halogen, cyano, amino, hydroxyl, carboxyl, ester, C 1-12 Alkyl, C 1-12 Alkoxy, C 2-12 Alkenyl, C 2-12 Alkynyl, C 3-12 Cycloalkyl, 4-12 membered heterocycloalkyl, C 6-12 Aryl or 5-12 membered heteroaryl, -L4-C(O)-(CH2CH2O) n3 -R, -C(O)-NR-(CHR) m2 -NR-C(O)-(CH2CH2O) n3 -R; L3 is a peptide residue [Am] p1 -: where p1 is 0, 1, 2, 3, 4, 5, 6, 7 or 8; Y is selected from the group consisting of -C(O)-, -OC(O)-, -NHC(O)-, -NR-(CHR) m2 -NR-C(O)-、-NR-(CHR) m2 -NR-C(O)O-(CHR) m1 -, chemical bonds; Wherein, each of the R is independently selected from the following groups: H, D, (CH2) n4 NHC(O)NH2, C1-C6 alkyl; m1, m2 and n3 are each independently selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12; m101 is selected from 0, 1, 2, 3, 4; Unless otherwise specified, the term "substituted" refers to the substitution of one or more hydrogen atoms on a group by a substituent selected from the group consisting of a hydrogen atom, a deuterium atom, a halogen, a nitrile group, a nitro group, a hydroxyl group, an amino group, a C1-C6 alkyl-NH-, a (C1-C6 alkyl)2N-, a C1-C6 alkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy group, a halogenated C1-C6 alkyl group, a halogenated C2-C6 alkenyl group, a halogenated C2-C6 alkynyl group, a halogenated C1-C6 alkoxy group, an allyl group, a benzyl group, a C6-C 12 Aryl, C1-C6 alkoxy-C1-C6 alkyl, C1-C6 alkoxy-carbonyl, phenoxycarbonyl, C2-C6 alkynyl-carbonyl, C2-C6 alkenyl-carbonyl, C3-C6 cycloalkyl-carbonyl, C1-C6 alkyl-sulfonyl, phenyl, 5-7 membered heteroaryl, C3-C8 cycloalkyl, 3-12 membered heterocyclyl, or C(O)NH-L2H.
3. The immunoconjugate according to claim 2, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or its pharmaceutically acceptable salt or hydrate, characterized in that: The L1 is 4. The immunoconjugate according to claim 2, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or its pharmaceutically acceptable salt or hydrate, characterized in that: The L2 is a group selected from the group consisting of: optionally substituted -(CHR) m1 -, optionally substituted -(CHR) m1 -C(O)NH-(CH2CH2O) n3 -(CHR) m2 -, optionally substituted -(CHR) m1 -(CH2CH2O) n3 -(CHR) m2 -; p1 is 0; The L4 is a chemical bond.
5. The immunoconjugate according to claim 2, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or its pharmaceutically acceptable salt or hydrate, characterized in that: The L2 is a group selected from the group consisting of: optionally substituted -(CHR) m1 -C(O)NH-(CH2CH2O) n3 -(CHR) m2 -; p1 is 0; The L4 is a chemical bond.
6. The immunoconjugate according to claim 2, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or its pharmaceutically acceptable salt or hydrate, characterized in that: The L2 is a group selected from the group consisting of: optionally substituted -(CHR) m1 -, optionally substituted -(CHR) m1 -(CH2CH2O) n3 -(CHR) m2 -; p1 is 0; The L4 is a chemical bond.
7. The immunoconjugate according to claim 2, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or its pharmaceutically acceptable salt or hydrate, characterized in that: The L2 is a group selected from the group consisting of: optionally substituted -(CHR) m1 -C(O)-; p1 is 1, 2, or 3; The L4 is an optionally substituted group selected from the following group:
8. The immunoconjugate according to claim 2, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or its pharmaceutically acceptable salt or hydrate, characterized in that: The L2 is a group selected from the following group: optionally substituted (CHR) m1 -C(O)-; p1 is 1, 2, or 3; The L4 is an optionally substituted group selected from the following group:
9. The immunoconjugate according to claim 2, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or its pharmaceutically acceptable salt or hydrate, characterized in that: The L2 is a group selected from the following group: optionally substituted -(CH2) m1 -C(O)-, optionally substituted -(CH2CH2O) n3 -(CHR) m2 -C(O)-, optionally substituted -(CHR) m1 -C3-C9 cycloalkyl-(CHR) m2 -; Preferably, m1 and m2 are each independently selected from 0, 1, 2, 3, 4 or 5; n3 is selected from 0, 1 or 2; p1 is 0; The L4 is a chemical bond, or an optionally substituted group selected from the following group:
10. The immunoconjugate according to claim 2, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or its pharmaceutically acceptable salt or hydrate, characterized in that: The L2 is a group selected from the group consisting of: optionally substituted -(CHR) m1 -C(O)-L4-NH(RCH) m1 -(OCH2CH2) n3 -(CHR) m2 -, optionally substituted -(CHR) m1 -C(O)NH-(CHR) m1 -5-10 membered aromatic heterocycle-(CH2CH2O) n3 -(CHR) m2 -, optionally substituted -(CHR) m1 -C(O)-L4-NH-(CH2CH2O) n3 -L4-(CHR) m2 -, optionally substituted -(CHR) m1 -C(O)-L4-NH(RCH) m1 -(OCH2CH2) n3 -L4-(CHR) m2 -; Preferably, the 5- to 10-membered aromatic heterocycle is a 5- or 6-membered aromatic heterocycle p1 is 0; The L4 is a chemical bond, or an optionally substituted group selected from the following group:
11. The immunoconjugate according to claim 2, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or its pharmaceutically acceptable salt or hydrate, characterized in that: The L3 is a peptide residue consisting of amino acids selected from the following group: phenylalanine, isoleucine, leucine, tryptophan, valine, methionine, tyrosine, alanine, threonine, histidine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, proline, citrulline, aspartic acid and glycine.
12. The immunoconjugate according to claim 2, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or its pharmaceutically acceptable salt or hydrate, characterized in that: The L3 is a peptide residue consisting of amino acids selected from the following group: glycine, alanine, lysine, phenylalanine, valine and citrulline.
13. The immunoconjugate according to claim 2, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or its pharmaceutically acceptable salt or hydrate, characterized in that: The L3 is a peptide residue selected from the following group: -Glycine-Phenylalanine-Glycine-(-Gly-Phe-Gly-), -Glycine-Glycine-Phenylalanine-Glycine-(-Gly-Gly-Phe-Gly-), -Valine-Citrulline-(-Val-Cit-), -Citrulline-Valine-(-Cit-Val-), -Citrulline-Alanine-(-Cit-Ala-), -Valine-Alanine-(-Val-Ala-), -Valine-Arg-), -Valine-Lysine-(-Val-Lys-), -Valine-Lysine (Ac)-(-Val-Lys (Ac)-), -Lysine-Valine-(-Lys-Val-), -Leucine-Citrulline-(-Leu-Cit-), -Isoleucine-Citrulline-(-Ile-Cit-), -Tryptophan-Citrulline-(-Trp-Cit-), -Phenylalanine-Lysine-(-Phe-Lys-), -Phenylalanine-Lys(Ac)-(-Phe-Lys(Ac)-), -Phenylalanine-Citrulline-(-Phe-Cit-), -Phenylalanine-Ala-(-Phe-Ala-), -Phenylalanine-Arginine-(-Phe-Arg-), -Alanine-Lysine-(-Ala-Lys-), - Alanine-Alanine-(-Ala-Ala-), -Alanine-Alanine-Alanine-(-Ala-Ala-Ala-), -Alanine-Alanine-Asparagine-(-Ala-Ala-Asn-), -Alanine-Alanine-Aspartic Acid-(Ala-Ala-Asp-), -Lysine-Alanine-Alanine-Asparagine-(-Lys-Ala-Ala-Asn-), -Lysine-Alanine-Alanine-Aspartic Acid-(-Lys-Ala-Ala-Asp-), -(D)-Valine-Leucine-Lysine-(-D-Val-Leu-Lys-), -Glycine-Glycine-Arginine -(-Gly-Gly-Arg-), -Glycine-Glycine-Asparagine-(-Gly-Gly-Asn-), -Glycine-Glycine-Phenylalanine-(-Gly-Gly-Phe-), -Valine-Lysine-Glycine-(-Val-Lys-Gly-), -Glutamic acid-Alanine-Alanine-(-Glu-Ala-Ala-), -Aspartic acid-Alanine-Alanine-(-Asp-Ala-Ala-), -Valine-Lysine-Glycine-Glycine-(-Val-Lys-Gly-Gly-), and -Lysine-Alanine-Asparagine-(-Lys-Ala-Asn-).
14. The immunoconjugate according to claim 2, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or its pharmaceutically acceptable salt or hydrate, characterized in that: The L3 is a structure selected from the following group:
15. The immunoconjugate according to claim 2, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or its pharmaceutically acceptable salt or hydrate, characterized in that: The L4 is a chemical bond, or an optionally substituted group selected from the following group: Among them, the R a and R b Each is independently selected from the following group: hydrogen, optionally substituted C1-C4 alkyl, optionally substituted C1-C4 deuterated alkyl.
16. The immunoconjugate according to claim 15, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or its pharmaceutically acceptable salt or hydrate, characterized in that: The L4 is a chemical bond, or an optionally substituted structure selected from the following group:
17. The immunoconjugate according to claim 2, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or its pharmaceutically acceptable salt or hydrate, characterized in that: The Y is -C(O)-, -OC(O)-, -NHC(O)-, or a chemical bond.
18. The immunoconjugate according to claim 1, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or its pharmaceutically acceptable salt or hydrate, characterized in that: L 11 Selected from the group consisting of -O-, -NH- or -S-.
19. The immunoconjugate according to claim 1, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or its pharmaceutically acceptable salt or hydrate, characterized in that: R1 is selected from the following group: C 1-12 Alkyl, C 2-12 Alkenyl, C 2-12 Alkynyl, C 3-12 Cycloalkyl or 4-12 membered heterocycloalkyl; and the R1 may be further replaced by one or more R 1a Substituents, and the R 1a Selected from the group consisting of halogen, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, -NR a1 R a2 、-NHC(=O)-R a3 , one or more R a4 Substituted 5-6 membered heteroaryl, -OC(=O)R a5 、-C(=O)R a5 、-OC(=O)OR a5 、-C(=O)OR a5 .
20. The immunoconjugate according to claim 1, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or its pharmaceutically acceptable salt or hydrate, characterized in that: The R1 is selected from the following group: C 1-12 Alkyl, C 2-12 Alkenyl, C 2-12 Alkynyl, C 3-12 Cycloalkyl or 4-12 membered heterocycloalkyl; and the R1 may be further replaced by one or more R 1a Substituents, and the R 1a Selected from the group consisting of halogen, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3- 6-cycloalkyl.
21. The immunoconjugate according to claim 1, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or its pharmaceutically acceptable salt or hydrate, characterized in that: R1 is selected from the following group: H, C 1- 8 alkyl, C 1-8 Alkoxy, C 2-8 Alkenyl, C 2-8 Alkynyl, C 3-8 Cycloalkyl or 4-8 membered heterocycloalkyl; wherein said R1 may be further replaced by one or more R 1a Substituents, and the R 1a Selected from the group consisting of hydrogen, halogen, hydroxyl, cyano, C 1-4 Alkyl, C 1- 4 Alkoxy.
22. The immunoconjugate according to claim 1, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or its pharmaceutically acceptable salt or hydrate, characterized in that: B does not exist, or B is selected from the following group: C 3-8 Cycloalkyl, 4-7 membered heterocyclic group, C 6-10 Aryl, or 23. The immunoconjugate according to claim 1, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or its pharmaceutically acceptable salt or hydrate, characterized in that: L 12 Selected from the following group: -(CR 1b R 1c ) p -(NR 1d ) q -、-O-、-S-、-(CR 1b R 1c ) p -C(=O)-、-(CR 1b R 1c ) p -C(=O)NH-, -(CR 1b R 1c ) p -NHC(=O)-, -S(=O)- or -S(=O)2-; wherein R 1b , R 1c Selected from the group consisting of hydrogen, halogen, C 1-6 Alkyl; R 1d is hydrogen or C 1-6 Alkyl; p is 0, 1, 2 or 3, and q is 0 or 1.
24. The immunoconjugate according to claim 1, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or its pharmaceutically acceptable salt or hydrate, characterized in that: R4 is selected from the group consisting of hydrogen, halogen, amino, hydroxyl, C 1-12 Alkyl, C 1-12 Alkoxy, C 2-12 Alkenyl, C 2-12 Alkynyl, C 3-10 Cycloalkyl, 4-10 membered heterocyclic group, C 6- 12 aryl, or 5-12 membered heteroaryl; and said R4 may be optionally replaced by one or more R e Substituent substitution; wherein R e Selected from the group consisting of hydrogen, halogen, hydroxy, carboxylic acid, amino, C 1-6 Alkyl, one or more R e1 Substituted C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 3-8 Cycloalkyl, 4-7 membered heterocyclyl, phenyl, 5-7 membered heteroaryl, -N(R e2 R e3 );where R e1 Selected from the group consisting of halogen, hydroxyl, -P(O)(OR e2 )2; R e2 , R e3 Selected from the group consisting of hydrogen, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 C substituted with halogenated alkyl or hydroxyl 1-6 alkyl.
25. The compound of formula I, its solvate, its prodrug, its metabolite, or its pharmaceutically acceptable salt according to claim 1, characterized in that: R5 is selected from the group consisting of halogen, hydroxy, cyano, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl.
26. The immunoconjugate according to claim 1, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or its pharmaceutically acceptable salt or hydrate, characterized in that: The toxin is selected from the group consisting of:
27. The immunoconjugate according to claim 1, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or its pharmaceutically acceptable salt or hydrate, characterized in that: The antibody is selected from the following group: a murine antibody, a chimeric antibody, a humanized antibody and a fully human antibody.
28. The immunoconjugate according to claim 27, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or its pharmaceutically acceptable salt or hydrate, characterized in that: The antibody is a monoclonal antibody.
29. The immunoconjugate according to claim 27, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or its pharmaceutically acceptable salt or hydrate, characterized in that: wherein the antibody is an antibody selected from the group consisting of anti-HER2 (ErbB2) antibody, anti-CD20 antibody, anti-TLR7 antibody, anti-EGFR antibody, anti-B7-H3 antibody, anti-c-Met antibody, anti-HER3 (ErbB3) antibody, anti-HER4 (ErbB4) antibody, anti-CD22 antibody, anti-CD30 antibody, anti-CD33 antibody, anti-CD44 antibody, anti-CD56 antibody, anti-CD70 antibody, anti-CD73 antibody, anti-CD105 antibody, anti-CEA antibody, anti-A33 antibody, anti-Cripto antibody, anti-EphA2 antibody, anti-G250 antibody, anti-MUCl antibody, anti-LewisY antibody, anti-VEGFR antibody, anti-GPNMB antibody, anti-Integrin antibody, anti-PSMA antibody, anti-Trop-2 antibody, anti-DLL3 antibody, anti-Tenascin-C antibody, anti-SLC44A4 antibody and anti-Mesothelin antibody; Preferably, the antibody is selected from Trastuzumab (Herceptin), Rituximab, Pertuzumab, Nimotuzumab, Enoblituzumab, Emibetuzumab, Inotuzumab, Pinatuzumab, Brentuximab, Gemtuzumab, Bivatuzumab, Lorvotuzumab, cBR96 and Glematumamab.
30. The immunoconjugate of claim 1 or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or its pharmaceutically acceptable salt or hydrate, characterized in that: The immunoconjugate is selected from the group consisting of:
31. An immunoconjugate precursor, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or a pharmaceutically acceptable salt or hydrate thereof, wherein the immunoconjugate precursor comprises the structure shown in Formula IA: LD(IA), in, L is L 1A -L2-L3-L4-Y-; among them, L 1A for Among them, R d is H, C1-C6 alkyl, C1-C6 deuterated alkyl, C3-C8 cycloalkyl or C3-C8 deuterated cycloalkyl; D is defined as in any one of claims 1-30.
32. The immunoconjugate precursor of claim 31, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or a pharmaceutically acceptable salt or hydrate thereof, wherein the immunoconjugate precursor is selected from the group consisting of:
33. A linker precursor as shown in formula (L-1), which is used to obtain a ligand-drug conjugate formed by connecting a drug unit to a ligand: L 1A -L2-L3-L4-YR g (L-1), in, L 1A for Among them, R d is H, C1-C6 alkyl, C1-C6 deuterated alkyl, C3-C8 cycloalkyl or C3-C8 deuterated cycloalkyl; R g is H, OH, O(C1-C6 alkyl), O(p-nitrophenyl); the remaining groups are defined as described in any one of claims 1-30.
34. A pharmaceutical composition comprising the immunoconjugate of any one of claims 1 to 30, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, prodrug or solvate thereof, and optionally a pharmaceutically acceptable carrier, diluent or excipient.
35. Use of the immunoconjugate described in any one of claims 1 to 30, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or its pharmaceutically acceptable salt, prodrug or solvate, and / or the pharmaceutical composition described in claim 34 in the preparation of a medicament for treating or preventing viral infection or tumor.
36. The use according to claim 35, wherein the tumor is a cancer associated with abnormally increased activity or expression of TLR7, HER2, HER3, B7H3, CD20 or EGFR.
37. The use according to claim 35, characterized in that The tumor is a tumor associated with the expression of the target targeted by the antibody in the immunoconjugate; preferably, the tumor includes a tumor with high expression of the target and / or a tumor positive for the target.
38. A linker as shown in formula (L-2), which connects a drug unit to a ligand to form a ligand-drug conjugate: -L1-L2-L3-L4-Y-(L-2), in, The definitions of L1, L2, L3, L4, and Y are as described in any one of claims 1-30.
Citation Information
Patent Citations
Kinase inhibitors
CN102695416A
Amino-substituted bicyclic inhibitor as well as preparation method and application thereof
CN115043842A
Chemical compounds
WO2010019637A1
Novel heteroaryl and heterocycle compounds, compositions and methods
WO2016119707A1
Preparation method and application of antibody drug conjugate
WO2022228493A1
Cited By
Linker-bioactive molecule conjugate and pharmaceutical use thereof
WO2026130483A1
